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THESIS OUTLINE 
This Thesis was structured in the following described manner. 
In the Abstract a summary of the Thesis was presented. 
In Chapter 1, Rationale, it was explained the motivations behind this Thesis conduction and the 
relevance of diabetic foot ulcer (DFU) prediction, prognosis and for the creation of a combined 
stratification classification system. 
In Chapter 2, the Aims of this Thesis were exposed. 
In Chapter 3, Background, (section 3.1) it was made a description of the methods for clinical decision 
rules’ (a specific type of stratification classification systems) development, validation and updating. 
Diabetes mellitus (DM) and its foot-related complications [namely DFU and lower extremity 
amputation (LEA)] epidemiology and costs at individual and societal levels (section 3.2) and a brief 
pathophysiological path for their development were described (section 3.3). Also, a sum up of the up-
to-date recommendations for DFU and consequent LEA prevention as well as the European quality 
of diabetic foot care were presented (section 3.4).  
Chapter 4, DFU prediction, includes 1 submitted and 3 published original studies. Firstly, we assessed 
the available evidence concerning risk stratification classification systems (section 4.1) and individual 
predictive variables (section 4.2) for DFU development risk assessment.  Next, we retrospectively 
validated all the available systems in a consecutive series of patients with DM without an active DFU 
in a Hospital setting (section 4.3) to understand if any system outperformed the remaining, evaluate 
the refinement pertinence and allow sample size calculation for further studies. Last, using all these 
results, we prospectively validated all of the systems in a multicentre context, evaluating the systems’ 
and their composing variables’ prognostic accuracy (section 4.4). 
Chapter 5, DFU prognosis, includes 3 published original studies where we conducted similar steps 
to those described in the previous chapter: classification systems (section 5.1) identification by 
systematic review, and prospective validation of all the available systems for DFU prognosis 
estimation (section 5.3) in a consecutive series of patients with DM and active DFU. In addition, the 
quality of diabetic foot care in a Portuguese diabetic foot clinic was assessed (section 5.2). 
We also included 1 published original study proposing a unified classification system, in Chapter 
6, having as foundation a classification proved valid for DFU development prediction (in Chapter 4) 
that, with the inclusion of additional DFU characterization variables (identified in Chapter 5), could 
also accurately predict LEA (the poorest DFU prognostic) in patients with active DFU. 
In Chapter 7 general conclusions of this Thesis and future research were presented. 
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RESUMO 
INTRODUÇÃO 
 
O grupo de patologias denominada de Pé Diabético, principalmente a úlcera e a amputação 
podológica, têm um grande impacto a nível de recursos financeiros e humanos do Sistema Nacional 
de Saúde, assim como na qualidade de vida dos utentes. Deste modo, as recomendações existentes 
sublinham a importância da sua prevenção através de diversas medidas, com especial ênfase na 
identificação e referenciação para clínicas especializadas dos utentes com Diabetes mellitus (DM) e 
em risco de desenvolvimento de complicações podológicas. 
No entanto, as decisões relativas à prevenção e tratamento destas complicações (por exemplo, o 
nível de cuidados, periodicidade das consultas, necessidade de intervenções educativas ou médicas, 
avaliação da eficácia do tratamento, etc.) são frequentemente realizadas tendo por base classificações 
com uma estrutura variada com rara avaliação da sua validade e reprodutibilidade. Deste modo, 
nenhuma classificação foi universalmente adoptada como referência para a estratificação por grau de 
risco de desenvolvimento de complicações a nível podológico dos utentes com DM na prática clínica. 
 
OBJECTIVOS 
 
Este projecto teve como objectivo último aumentar o nível da evidência disponível sobre como 
classificar o Pé do utente com DM e propor um sistema unificado que permita estratificar estes 
indivíduos pelo seu risco de úlcera e amputação assim como promover o uso, pelos profissionais de 
Saúde, de uma classificação simples, clinicamente plausível e baseada na evidência.  
Para concretizar tal, vários passos foram definidos dentro de cada secção com os seguintes 
objectivos: 
1. Para a predição de úlcera: 
1.1 identificar as classificações e variáveis existentes para a predição deste desfecho 
clínico, através de revisões sistemáticas, e 
1.2 validar e comparar as classificações existentes numa série consecutiva de sujeitos 
com DM sem úlcera activa. 
2. Para o prognóstico de úlcera: 
2.1 identificar as classificações e as variáveis existentes para a predição de mau 
prognóstico de úlcera (i. e., amputação), através de revisões sistemáticas, 
2.2 validar e comparar as classificações existentes para a determinação do prognóstico 
de úlcera numa série consecutiva de sujeitos com DM e úlcera activa. 
3. Criar uma classificação unificada que possa ser utilizada para predizer ambos os desfechos 
clínicos em estudo (úlcera e amputação), tendo por base o resultado das etapas anteriores. 
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MÉTODOS 
 
Para cada desfecho clínico desenvolvemos revisões sistemáticas em diversas bases de dados e 
incluindo estudos que analisassem o valor preditivo e/ou validade de variáveis independentes e 
classificações associadas com o desenvolvimento de úlcera podológica, em sujeitos sem lesão activa, 
e associadas com a ocorrência de amputação, nos sujeitos com úlcera presente. Métodos de meta-
análise foram aplicados, sempre que possível. 
A validação das diversas classificações existentes para a estratificação dos sujeitos com DM pelo 
seu risco de desenvolver uma úlcera a nível podológico foi conduzida sob a forma de estudo de coorte 
inicialmente num centro único e de forma retrospectiva e posteriormente em contexto multicêntrico 
e de forma prospectiva.  
Para o primeiro estudo, foram incluídos todos os sujeitos com DM e sem úlcera activa que 
recorreram à consulta de Podologia do Centro Hospitalar de Vila Nova de Gaia/ Espinho EPE 
(CHVNG), de Janeiro de 2008 a Dezembro de 2010 (n=364).  
Para o segundo, foram incluídos todos os sujeitos que recorreram à mesma consulta, de 
Dezembro de 2010 a Dezembro de 2012; assim como às consultas de rastreio na Unidade de Saúde 
Familiar (USF) Aquae Flaviae, de Julho de 2013 a Setembro de 2014; e na USF de Santo André de 
Canidelo, de Março a Setembro de 2014 (n= 446). Os participantes foram seguidos até o 
desenvolvimento de úlcera, morte ou até 1 ano. 
De seguida, um estudo de coorte retrospectivo foi desenvolvido incluindo todos os sujeitos 
observados como primeiras consultas de Pé Diabético do CHVNG, de Janeiro de 2011 a Dezembro 
de 2013 (n=950 consultas, 813 sujeitos). Os dados para a caracterização do pedido de referenciação, 
dos sujeitos e subsequente resultado clínico foram colhidos e comparados com os reportados pelo 
consórcio Europeu Eurodiale de forma a melhor contextualizar os resultados dos estudos seguintes. 
A validação dos sistemas de classificação utilizados para a estimativa de prognóstico de úlcera e 
consequente necessidade de amputação foi realizada como um estudo de coorte prospectivo 
unicêntrico, incluindo todos os sujeitos com DM e úlcera activa a nível podológico que recorreram à 
consulta de Pé Diabético do CHVNG, entre Janeiro de 2010 e Março de 2013 (n=293). Os 
participantes foram seguidos até cicatrização, amputação ou por pelo menos 3 meses. 
Nos estudos de validação a associação entre as variáveis e classificações com o desfecho clínico 
foi analisada e as diversas medidas de validade diagnóstica/ prognóstica foram calculadas 
(nomeadamente, sensibilidade, especificidade, likelihood ratios, valores preditivos e área sobre a curva 
ROC). Os respectivos intervalos de confiança a 95% foram comparados entre as classificações de 
forma a detectar diferenças estatisticamente significativas.  
Finalmente, uma classificação refinada e unificada foi desenvolvida, utilizando os dados recolhidos 
nos estudos anteriores, técnicas de regressão logística e recalculando as respectivas medidas de 
validade diagnóstica/prognóstica e os seus intervalos de confiança a 95%, dando especial ênfase à 
área sob a curva ROC. 
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RESULTADOS 
 
Na primeira revisão sistemática verificamos que existem 5 classificações para a predição de 
desenvolvimento de úlcera que foram propostas ou validadas em 13 estudos, nomeadamente da 
Universidade do Texas, do Grupo Internacional de Trabalho em Pé Diabético (conhecida como 
IWGDF), da Rede de Guidelines Intercolegial Escocesa (SIGN), da Associação Americana de 
Diabetes (ADA) e de Boyko e colegas. 
Observamos que 5 variáveis foram incluídas em praticamente todos os sistemas: neuropatia 
diabética periférica (NDP), doença arterial periférica (DAP), deformidade podológica e história prévia 
de úlcera ou amputação. O número de factores predictivos incluídos assim como o número de grupos 
de risco variou de 4 a 8 e de 2 a 6, respectivamente. 
A descrição de medidas de validade foi escassa e a validação externa tinha ocorrido apenas para a 
classificação de Boyko e colegas. 
Na segunda revisão sistemática, identificamos mais de 100 variáveis preditivas analisadas em 71 
estudos. As variáveis mais frequentemente analisadas foram a idade, o género, duração da diabetes, 
índice de massa corporal, hemoglobina glicada e NDP. A maioria das restantes variáveis foram 
avaliadas em 2 ou menos estudos. 
As variáveis mais comumente incluídas nas classificações de risco (NDP, DAP, deformidade 
podológica e complicação podológica prévia) demonstraram estar consistentemente associadas com 
a ocorrência de úlcera em diversos estudos.  
Em ambas as revisões a prevalência de úlcera descrita em cada um dos estudos incluídos variou 
substancialmente. Métodos meta-analíticos não foram possíveis de ser aplicados. 
Na validação retrospectiva das classificações utilizadas para a predição de desenvolvimento de 
úlcera verificamos que, na nossa coorte, existe uma associação entre a idade, duração da diabetes, 
deformidade podológica, DAP, NDP e história prévia de úlcera ou amputação com a ocorrência do 
desfecho clínico em estudo. Verificou-se também uma associação entre os diferentes grupos de risco 
de todas as classificações e o desenvolvimento de úlcera. 
As várias classificações apresentaram valores robustos de validade (principalmente valores 
preditivos negativos) sem diferenças estatisticamente significativas entre elas. No entanto, o valor 
preditivo positivo foi em todos os casos inferior a 30%, os likelihood ratios positivos a 4 e os negativos 
superiores a 0.1 – o que representa um importante potencial de optimização. 
Os resultados do estudo de validação prospectiva multicêntrica foram de encontro ao estudo 
anterior, isto é, as diferentes classificações apresentaram valores substanciais de validade diagnóstica 
e não se verificaram diferenças significativas entre elas, apesar de ter um tamanho amostral superior. 
Globalmente, as classificações demonstraram ser válidas e comparáveis para a maioria das medidas e 
pontos de corte. Os valores preditivos positivos foram inferiores a 40% na maioria dos cenários, mas 
os valores preditivos negativos foram sempre superiores a 90%. Para todas as classificações a área 
sob a curva ROC foi igual ou superior a 0.75. Verificaram-se diferenças nas características dos sujeitos 
assim como na validade das classificações entre o contexto hospitalar e o de cuidados de saúde 
primários. 
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No que diz respeito à predição de amputação, foram encontrados 8 sistemas para a descrição e 7 
para a estimativa de prognóstico de úlceras podológicas em indivíduos com DM. A prevalência da 
amputação variou entre 6 e 33%. 
Tal como com as classificações para a predição de desenvolvimento de úlcera, o número de 
factores preditivos incluídos variou substancialmente (de 1 a 9). As variáveis mais frequentemente 
incluídas foram a presença de DAP (n=12), infecção (n= 10) e profundidade da úlcera (n=10). As 
classificações de Meggit-Wagner, S(AD)SAD e da Universidade do Texas foram as mais validadas, 
enquanto que as restantes 10 classificações foram apenas derivadas ou validadas uma vez. 
De novo, as medidas de validade foram escassamente reportadas com apenas 5 estudos 
apresentando-as e 8 permitindo o seu cálculo. A sensibilidade das classificações variou de 38 a 100%, 
especificidade de 30 a 88%, valores preditivos negativos foram sempre superiores a 80% enquanto 
que os positivos foram sempre inferiores a 60%. Apenas dois estudos descreveram a área sob a curva 
ROC apresentando valores de 0.66 e 0.80. 
Meta-análise foi possível apenas para a validade das variáveis incluídas. Os valores agregados de 
validade variaram entre 0.65 (para a presença de gangrena) e 0.74 (para a presença de infecção). 
O principal motivo de referenciação para a nossa consulta foi a presença de úlcera activa (70%). 
Em comparação com a população dos estudos do Eurodiale, a nossa amostra era ligeiramente mais 
velha, com úlceras mais profundas e graves e mais frequentemente localizadas a nível digital. 
Relativamente ao desfecho clínico ocorreu cicatrização, amputação major e morte numa proporção 
similar, mas menos amputações minor e hospitalizações. 
Na validação simultânea das classificações existentes para a caracterização de úlcera ou avaliação 
do seu prognóstico verificamos que todas se encontram associadas com o risco de amputação. As 
classificações apresentaram tipicamente sensibilidades superiores a 80%, likelihood ratios negativos 
inferiores a 0.5 para os grupos de alto risco; a área sob a curva ROC variou entre 0.56 e 0.83 e os 
likelihood ratios positivos entre 1.0 e 5.9. Não ocorreram diferenças estatisticamente significativas 
entres os sistemas. 
Após tudo isto, consideramos pertinente o refinamento das classificações existentes e propor uma 
nova classificação (designada de DIAFORA) com uma particularidade: esta classificação é composta 
por 2 partes e pretende predizer 2 objectivos clínicos. 
Após as nossas revisões sistemáticas para identificar as classificações existentes para a predição e 
para o prognóstico de úlcera, constatou-se que as variáveis mais frequentemente usadas para prever 
o desenvolvimento de úlceras também estavam incluídas em diversas classificações para prever 
amputações. As variáveis em questão seriam a presença de NDP, DAP, deformidade podológica e 
história prévia de úlcera ou amputação. 
De facto, este grupo de 4 variáveis corresponde a uma das classificações mais utilizadas para 
identificar sujeitos com DM e pé em risco: a classificação do IWGDF. Esta classificação provou ter 
uma validade equiparável às restantes, quer no estudo multicêntrico prospectivo, quer no 
retrospectivo. Assim consideramos que a primeira parte da DIAFORA deveria ser composta pela 
classificação IWGDF e deveria ser a ferramenta de eleição para indivíduos sem úlcera activa quando 
se pretende determinar o risco de a desenvolverem. 
Após o aparecimento de úlcera, devem ser adicionadas 4 variáveis de modo a prever a ocorrência 
de amputação. Esta segunda parte da classificação DIAFORA é composta por variáveis de 
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caracterização da úlcera (a presença de múltiplas úlceras, infecção, gangrena e atingimento ósseo). A 
seleção destas variáveis decorreu de uma análise por regressão logística. 
Portanto, a primeira parte da DIAFORA já tinha sido validada para prever o desenvolvimento de 
úlceras em artigos prévios. Ao aplicar a DIAFORA no seu todo, observamos que esta classificação é 
válida para prever a ocorrência de amputações. Para a predição de ocorrência de amputação, como 
score, a DIAFORA apresentou uma área sob a curva ROC de 0.91 e sob a forma de categorias de risco 
de 0.89. O grupo de alto risco apresentou um likelihood ratio positivo de 5 e um valor preditivo positivo 
de 58.  
Quando comparada com as outras classificações existentes, esta classificação apresentou valores 
de validade diagnóstica iguais ou superiores às restantes em termos de predição de amputação em 
indivíduos com úlcera. 
 
CONCLUSÕES 
 
Consideramos que a criação de um sistema unificado para estratificação de indivíduos com DM 
de acordo com o risco de desenvolverem úlceras ou amputação podológicas, que seja simples, 
baseado em evidência e clinicamente relevante irá promover a sua adopção e utilização pelos 
profissionais de saúde. Pretende-se ainda que a utilização seja padronizada quer na prática clínica 
diária, quer na investigação. Para atingir este objectivo e criar a DIAFORA, foi necessário 
primeiramente retirar várias conclusões. 
Apesar da importância da identificação do pé em risco de ulceração e amputação, concluímos que 
as classificações existentes para ambos os desfechos clínicos apresentam um baixo nível de evidência 
por falta de estudos de validação, bem como de estudos de análise de reprodutibilidade. Assim, pela 
primeira vez, realizamos uma validação externa de todas as classificações em simultâneo para a 
predição de úlcera e de amputação numa coorte de indivíduos sem e outra com úlcera activa, 
respectivamente. Deste modo as classificações usadas para cada um dos desfechos clínicos foram 
comparadas directamente para identificar a mais válida assim como analisar a pertinência da sua 
melhoria. 
De um modo geral a validade dos sistemas era boa, sem diferenças estatisticamente significativas 
entre as classificações, pelo que nenhuma pôde ser considerada como a melhor. 
Além disso, os baixos valores preditivos positivos e de lilkelihood ratio, tornaram pertinente 
melhorar as classificações e a criação de um sistema unificado. A DIAFORA apresenta uma estrutura 
facilmente memorizável e com procedimentos simples para a recolha de variáveis. Mostrou ainda ter 
uma validade igual ou superior na predição de amputação em indivíduos com úlcera, em relação às 
classificações já existentes, o que comprova o seu valor para uso na prática clínica. 
Salientamos que os resultados clínicos da consulta multidisciplinar de Pé Diabético onde 
decorreram a maioria dos estudos que compõem esta Tese são semelhantes aos descritos a nível 
Europeu pelo consórcio Eurodiale. Consideramos por isso que os nossos resultados são 
generalizáveis aos centros de Pé Diabético europeus. 
Apesar destes progressos, consideramos essencial desenvolver mais investigação no sentido de 
clarificar se a estratificação de risco no Pé Diabético aplicada à prática clínica tem um verdadeiro 
impacto na prevenção das complicações e validando externamente a nossa classificação DIAFORA. 
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ABSTRACT 
RATIONALE 
 
Diabetic foot complications, namely ulcer (DFU) and amputation (LEA), have a great impact in 
National Health Systems’ financial and human resources as well as in patients’ quality of life. Thus, 
available recommendations highlight the importance of their prevention by the application of diverse 
measures, especially the identification and referral to specialized centres of patients with DM at risk 
of foot complications development. 
However, everyday decisions linked to the prevention and treatment of these complications (for 
example, health institution level of care, appointments periodicity, need for educational or medical 
intervention, treatment efficacy assessment, etc.) are based on classifications rarely validated or with 
their accuracy compared. Not surprisingly, no single classification for the stratification of subjects by 
their risk of foot complications has been adopted as gold-standard for clinical practice. 
 
PURPOSE AND AIMS 
 
This research had as ultimate purpose to increase the level of available evidence on how to classify 
the diabetic foot and propose a unified system to stratify subjects with diabetes according to their 
risk of DFU and LEA and to promote the use and adoption, by the healthcare professionals, of a 
simple, clinically plausible and evidence-based classification system. 
To achieve this, several steps were defined within each main section with the following aims: 
1. For the DFU prediction, 
1.1 to retrieve, through systematic review, all the stratification systems created and variables 
assessed for the DFU development prediction in subjects with DM but without active 
DFU, and 
1.2 to validate all the available systems for DFU development prediction in a consecutive 
series of patients without active DFU; 
2. for the DFU prognosis, 
2.1 to retrieve, through systematic review, all the stratification systems created and variables 
assessed for the LEA prediction in subjects with DM and active DFU, and 
2.2 to validate all the available systems for DFU prognostic assessment in a consecutive 
series of patients with active DFU; and finally 
3. to create a unified system that can be used to predict both outcomes (DFU and LEA), based 
on the previous stages’ results. 
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METHODS 
 
For each outcome we have started by conducting systematic reviews in diverse databases including 
studies that analysed the predictive value and/or accuracy of independent variables and classification 
systems for DFU development prediction, in subjects with DM without an active lesion, and LEA 
occurrence prediction, in those with an active lesion. Meta-analysis methods were applied, whenever 
possible. 
Validation of different classification systems available to stratify patients by their risk of DFU 
development was performed in a single centre retrospective study and latter in a multicentre 
prospective cohort study.  
For the first, all subjects with DM but without an active foot lesion that had a Podiatry 
appointment in Centro Hospitalar de Vila Nova de Gaia/ Espinho EPE (CHVNG), from January 
2008 to December 2010, were included (n=364).  
For the second, we included all subjects recurring to the same appointment, from December 2010 
to December 2012; as well as those undergoing podiatric screening in the Aquae Flaviae, from July 
2013 to September 2014; and Santo André de Canidelo, from March to September 2014, Family 
Health Units (n= 446). Subjects were followed until DFU development or for 1 year. 
Next, a retrospective cohort study including all subjects observed as first appointments in 
CHVNG Diabetic Foot Clinic, between January 2011 and December 2013, was conducted (n=950; 
813 subjects). Variables characterizing referral request, subjects and clinical outcome were collected 
and compared to the ones reported by the European consortium – Eurodiale in order to better 
contextualize the following studies’ results. 
Validation of the classification systems used for DFU prognostic and consequent necessity for 
LEA was conducted as a single centre prospective cohort study, including all subjects with DM and 
an active lesion recurring to the CHVNG Diabetic Foot Clinic, between January 2010 and March 
2013 (n=293). Subjects were followed until healing, LEA or at least 3 months. 
In all validation studies, component variables’ and classifications’ association with outcome was 
evaluated and different diagnostic/prognostic accuracy measures were calculated [namely, sensitivity, 
specificity, likelihood ratios, predictive values (PV) and area under the receiver operating 
characteristic curve (AUC)]. The measures’ respective 95% confidence intervals (CI) were compared 
between classifications in order to detect statistically significant differences. 
Finally, a refined and unified classification that can be used to predict both outcome was 
developed using the data collected in the previously described studies as well as logistic regression 
techniques, and by recalculating the respective diagnostic/prognostic accuracy measures, especially 
AUC, and their 95% CI. 
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RESULTS 
 
With the first systematic review, we identified 5 different stratification systems for the DFU 
development risk prediction that were proposed or validated in 13 studies; namely University of 
Texas, International Working Group on Diabetic Foot (IWGDF), Scottish Intercollegiate Guideline 
Network (SIGN), American Diabetes Association (ADA), and Boyko and colleagues.  
We observed that 5 variables were included in almost all the systems: diabetic peripheral 
neuropathy (DPN), peripheral arterial disease (PAD), foot deformity, and previous DFU and LEA. 
The number of variables included and of risk groups ranged from 4 to 8 and from 2 to 6, respectively. 
Accuracy measures reporting was unusual in these studies and external validation had been 
conducted only for the Boyko et al classification. 
In the second systematic review, we identified more than 100 predictive variables assessed in 71 
studies for the DFU development prediction. The variables most frequently assessed were age, 
gender, diabetes duration, body mass index, glycated haemoglobin and DPN. The majority of the 
identified variables were assessed by only two or fewer studies.  
The most commonly included variables in the stratification systems (DPN, PAD, foot deformity 
and previous foot complications) demonstrated to be consistently associated with DFU in several 
studies.  
In both reviews the DFU prevalence reported in each of the included studies varied greatly.  
Meta-analysis was not possible to be conducted. 
In the retrospective validation of the systems used for DFU prediction we found that age, diabetes 
duration, foot deformity, PAD, DPN, previous DFU and LEA were associated with DFU 
occurrence. There was also an association between the different systems’ risk groups and outcome 
occurrence. 
The diverse systems presented good accuracy values (mainly negative PV) and no statistically 
significance differences were found. Nevertheless, positive PV were all under 30%, positive LR 
inferior to 4 and negative LR were superior to 0.1. This represents an important potential for 
optimization. 
The multicentre prospective study results are in line to the previous one. The available 
classifications presented high accuracy values and no significant differences were observed, even with 
a higher sample size.  
Globally the classifications were highly valid and comparable for most of the measures and cut-
offs. Positive predictive values (PV) were inferior to 40% in the majority of the scenarios but negative 
PV were always superior to 90%. For all classifications the AUC was equal or superior to 0.75.  
Differences were found between characteristics of the participants and classifications’ validity 
according to the setting.  
On the subject of the prediction of LEA we found 8 systems for the description and 7 for the 
prognostic assessment of DFU that were addressed in 25 studies. LEA prevalence ranged from 6 to 
33%. 
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As with DFU development prediction systems, the number of included variables fluctuated widely 
(from 1 to 9). The most frequently included were the presence of PAD (n=12), infection at the ulcer 
site (n=10) and its depth (n=10). The Meggitt–Wagner, S(AD)SAD and Texas University 
Classification systems were the most extensively validated, whereas the remaining 10 classifications 
were just derived or validated only once.  
Once more, accuracy measures were scarcely reported with just 5 studies describing them and 8 
allowing their calculation. Systems’ sensitivity ranged from 38 to 100%, specificity 30 to 88%, negative 
PV were always over 80%, while positive PV were under 60%. Only two studies reported AUC values, 
presenting values of 0.66 and 0.80. 
Meta-analysis was only possible for the composing variables’ accuracy. Pooled accuracy ranged 
from 0.65 (for gangrene) to 0.74 (for infection). 
The main referral reason to our centre was the presence of an active DFU (70%). Comparing to 
the population included in the Eurodiale studies, our sample was slightly older, with deeper and more 
severe ulcers and more frequently located at the toes. Concerning clinical outcome we had similar 
healing, major amputation and death rates, but less minor amputations and hospitalization. 
Simultaneously validating the systems available for DFU characterization and/or prognostic 
assessment we verified that all were associated with LEA. Systems typically presented sensitivity 
values superior to 80% and negative LR inferior to 0.5 for the highest risk group; AUC ranged from 
0.56 to 0.83 and positive LR from 1.0 to 5.9. No significant differences were found between systems.  
Finally, we have considered as pertinent the refinement of the existing classifications and to create 
a new classification (named DIAFORA) with some particularities: this classification has two parts 
and two purposes.  
In our systematic reviews to identify the existing classifications for DFU prediction and for 
prognostic assessment, we have observed that the variables most frequently used for DFU 
development prediction; namely the presence of DPN, PAD, foot deformity and previous DFU or 
LEA; were also included in several classifications to predict LEA occurrence. In fact, this group of 
four variables corresponds to one of the most disseminated classifications to identify the diabetic 
foot at risk: the IWGDF classification. This classification proved to be equally valid in comparison 
to the remaining, both in our retrospective as in our prospective multicentre studies. So, we 
considered that the first part of the DIAFORA should be composed by the IWGDF classification 
and should be the selected tool to be used in subjects without active DFU to estimate their risk of 
developing one. 
Once a DFU has developed, four variables should be added, in order to accurately predict LEA 
occurrence. This second part of the DIAFORA classification is composed by DFU characterization 
variables (the presence of multiple DFU, infection, gangrene and bone affection) that were selected 
by logistic regression analysis. 
So, the first part proved to be valid for DFU development prediction in our first studies, and, 
when using DIAFORA in its entirety, we observed that this classification was valid for LEA 
occurrence prediction. As a continuous score DIAFORA had an AUC of 0.91 and as risk categories 
of 0.89 for LEA prediction. The high-risk group presented a positive LR of 5 and positive PV of 58. 
This classification presented similar or superior diagnostic accuracy measures for LEA prediction in 
DFU patients when compared with the existing ones. 
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CONCLUSIONS 
 
 
We considered that the creation of a unified system, to stratify subjects with DM according to 
their risk of DFU and LEA, which is evidence-based, simple and clinically plausible would promote 
the adoption and use, by healthcare professionals, of a standardized classification in daily clinical care 
and research conduction. To achieve this major goal and create the DIAFORA tool several 
conclusions were previously needed to be made. 
Despite the importance of an adequate identification of the foot at risk, for both DFU and LEA 
prediction, we concluded, in our systematic reviews, that the available literature presented a low 
evidence level due to a lack of validation studies, describing accuracy measures, as well as reliability 
assessment studies. Thus we have, for the first time, externally validated all the available classifications 
for each outcome simultaneously in the same cohorts of subjects, one without and one with an active 
DFU, respectively. This way, the classifications used for each one of the outcomes were directly 
compared to identify the most valid and their pertinence for refinement. 
In general, the systems’ accuracy was good, without significant statistical differences among them, 
meaning that no classification outperformed the remaining and none could be selected as the “best 
one”.  
Furthermore, low positive PV and LR values made pertinent the classifications’ refinement and 
the proposal of a unified system: DIAFORA. Our classification, in addition, to an easy to remember 
structure and the comprehensive manner for the selection of the variables to include, showed an 
equal or superior accuracy for LEA prediction in individuals with a DFU when compared to those 
available, which makes it valuable for clinical use. 
We highlight that the clinical results of the specialized diabetic foot clinic, where the majority of 
this Thesis’ studies were developed, were similar to those described at European level by the 
Eurodiale consortium. Therefore, we think that our results are generalizable for specialized diabetic 
foot centres around Europe.  
Despite all these progresses we consider essential future research clarifying if the diabetic foot risk 
stratification by itself, with clinical practice decisions in accordance, has a true impact on diabetic foot 
complications’ prevention and externally validating DIAFORA. 
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ACRONYMS AND ABBREVIATIONS 
1st   First 
3rd   Third 
5th   Fifth  
 
α  Intercept 
β  Slope 
 
ABI  Ankle–Brachial Index 
ADA  American Diabetes Association 
AOFAS American Orthopaedic Foot and Ankle Society 
ARR Absolute Risk Reduction 
AUC  Area Under the receiver operating characteristic Curve 
 
BMI  Body Mass Index 
 
CDC  Centers for Disease Control 
CDR Clinical Decision Rules 
CHS  Curative Health Services wound grade scale 
CI   Confidence Interval 
Cm2 Squared centimeter 
CONSORT  Consolidated Standards for Reporting Trials 
CRF  Case-Report Form 
CRP  C-Reactive Protein 
 
DAM Diagnostic Accuracy Measure 
DEPA  Depth of the ulcer, Extent of bacterial colonization, Phase of ulcer and Association 
aetiology classification system 
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DFU  Diabetic Foot Ulcer 
DIAFORA  DIAbetic FOot Risk Assessment 
DM  Diabetes Mellitus 
DN   Diabetic Neuropathy 
DPN  Diabetic Peripheral Neuropathy 
DUSS  Diabetic Ulcer Severity Score 
 
EASD European Association for the Study of Diabetes 
EPE Entidade Pública Empresarial 
EQ-5d EuroQoL quality of life questionnaire 
ESRD End-Stage Renal Disease 
EPV Events per Variable  
 
GRADE Grading of Recommendations Assessment Development and Evaluation 
 
HbA1c  Glycated haemoglobin 
HR   Hazard Ratio 
HrR-QoL Health Related Quality of Life 
Hz   Hertz 
 
IBM  International Business Machines corporation 
ICER Incremental Cost Effectiveness Ratio 
IDF  International Diabetes Federation 
IDSA  Infectious Disease Society of America 
IQR  Interquartile range 
IWGDF  International Working Group on Diabetic Foot 
 
l  Litre 
LE   Lower Extremity 
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LEA  Lower Extremity Amputation 
LR   Likelihood Ratio 
 
mg  milligrams  
mmHg  Millimetres of mercury 
MNCV  Motor Nerve Conduction Velocity 
MTPJ  Metatarsophalangeal Joint 
 
NA  Not Applicable 
NDS Neuropathy Disability Score 
NICE  National Institute for Health and Care Excellence 
NIH National Institutes of Health 
NNT Number Needed to Treat 
NPV  Negative Predictive Value 
 
OR   Odds Ratio 
 
PAD  Peripheral Arterial Disease 
PEDIS  Perfusion, Extent, Depth/tissue loss, Infection, Sensation classification system 
PI  Prognostic Index 
PODUS  Prediction Of Diabetic Foot Ulcerations 
PPP  Peak Plantar Pressure 
PPV  Positive Predictive Value 
PVD  Peripheral Vascular Disease 
 
ReDFU Diabetic Foot Ulcer Recurrence 
RCT  Randomized Controlled Trial 
RG  Risk Groups 
ROC  Receiver Operating Characteristic 
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RR  Relative Risk 
RRR Relative Risk Reduction 
 
S(AD)SAD Size (Area, Depth), Sepsis, Arteriopathy, Denervation system 
SEWSS  Saint Elian Wound Score System 
SIGN  Scottish Intercollegiate Guideline Network 
SINBAD  Site, Ischemia, Neuropathy, Bacterial infection, and Depth 
SPSS Statistical Package for Social Sciences 
SR   Systematic Review 
STARD  Standards for the Reporting of Diagnostic Accuracy Studies 
STROBE  Strengthening of the Reporting of Observational Studies in Epidemiology  
SWM  Semmes–Weinstein Monofilament 
 
TCC Total Contact Casting 
TRIPOD Transparent Reporting of multivariate prediction model for Individual Prognosis Or 
Diagnosis 
TUC  Texas University Classification 
 
USD United States Dollars 
UT   University of Texas 
UTFRS  University of Texas Foot Risk Stratification 
 
VPT  Vibration Perception Threshold  
 
WHO World Health Organization 
WHS Wound Healing Society  
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DIABETES MELLITUS RELATED COMPLICATIONS: THE IMPACT ON THE FOOT 
 
Diabetes mellitus (DM) is one of the most frequent metabolic disorders 1,2. Located in the North 
of Portugal, the Porto metropolitan area presents a global prevalence of 13.9%, including subjects 
with known and unknown diabetes, one of the highest in the country 3. Moreover, the constant and 
significant rise of DM prevalence combined with insufficient health care resources will increase even 
further the need for improvement in the ability to prevent and treat DM-related complications 4.  
There are seven most common complications described as related to DM. They are metabolic, 
retinopathy, nephropathy, cerebrovascular, cardiovascular, neuropathy and peripheral arterial disease 
(PAD) 5. Once established, diabetic peripheral neuropathy (DPN) and PAD lead to alterations on 
lower extremities’ sensitivity and blood flow which highly increase the risk of diabetic foot ulcer 
(DFU) development and lower extremity amputations (LEA) occurrence in subjects with DM 6. 
A DFU occurrence represents high costs for the National Health Systems and has a great impact 
on patients' life, namely through the form of persisting pain, impaired mobility, limited social activities 
and relationships, and respective family 7,8.  
Additionally, a systematic review with meta-analysis, including eight studies, reported that DFU 
was associated with an increased risk of all-cause mortality [relative risk (RR) of 1.89, 95% confidence 
interval (CI) 1.60-2.23), fatal myocardial infarction (2.22, 95% CI 1.09-4.53) and fatal stroke (1.41, 
95% CI 0.61-3.24)] 9. In fact, a study concluded that having a DFU increases the risk of mortality 
independently of age, gender, visual and physical impairment, diabetes duration, the number of 
diabetes-related complication and LEA history 10. 
Not surprisingly, current guidelines emphasise the need for early identification of feet at risk; 
education of the patient and family; the use of adequate footwear; direct and sustained follow-up; 
prompt treatment of non-ulcerative lesions 11 and adequate DFU classification and treatment 6. 
However, it was reported that costs used for DFU treatment are 10 times higher than those used for 
DFU prevention 12. In addition, authors considered that if adequate DFU treatment would prevent 
20% of hospitalization and LEA this would decrease in 22 million € treatment costs. But, if 50% of 
the DFU were prevented by adequate preventive care a total of 88 million € would be saved.  
 
DIABETIC FOOT COMPLICATIONS’ PREVENTION: THE IMPORTANCE OF SCREENING 
 
Although structured podiatric care should be available to all diabetic patients, with the existing 
resource limitation such is impossible and so foot problems’ treatment and prevention are frequently 
inadequate. Therefore, those in most need should be adequately identified and given priority. 
Prognostic stratification systems incorporating associated risk factors quick, easy and inexpensive to 
collect through foot examination or simple anamnesis are the most effective way for risk assessment 
and consequent resource allocation 4,13,14. 
Screening is defined as the use of rapid tests to identify certain condition or disease in subjects 
without signals of its existence. It is appropriate to conduct it if the health condition is serious; the 
natural history is understood; the condition is detectable in preclinical stage; available screening 
techniques are cheap, safe, reliable and valid; early treatment is more effective than late; treatment is 
safe and acceptable; facilities are adequate for diagnosis and treatment, and screening programs can 
improve outcomes and justify costs 15.  
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Diabetic foot screening fulfils all the described requisites. However, some authors affirmed that 
diabetic foot examinations in general practice and in hospitalized patients are both uncommon and 
unsatisfactory 16,17. This may be partly due to patients’ limited understanding of this condition 
potential impact, limited access to appropriate healthcare; professionals’ lack of time and/or training 
16, inaccurate comprehension of which variables to incorporate in regular screening 18 and the belief 
that intervention is unlikely to have a considerable impact on clinical outcome 19. 
Diabetic foot risk stratification is a component of diabetic foot screening, meaning, while the first 
describes the quantification of the risk an individual has of developing an outcome, the second starts 
with risk stratification but involves the application of subsequent effective interventions to prevent 
or manage the clinical condition at an initial stage 20. 
Stratification classification systems, in the form of clinical decision rules (CDR), are an essential 
tool for classifying patients with DM without DFU, according to their cumulative risk of DFU 
occurrence, and deciding allocation of scarce resources, that represent everyday reality for healthcare 
services.  
In the diabetic foot context, an adequate stratification system must be easy to use but also accurate 
in identifying patients at higher risk of developing a DFU consequently assisting health professionals 
in detecting patients for whom the most specialised care, orthotic resources, structured educational 
programmes and more frequent examinations should be provided 14. Doing so may diminish the 
unreasonably high level of foot-related morbidity and costs 14. 
Despite their importance, no review had been conducted in order to define and describe all the 
available stratification systems. In addition, experts stated that no system had been unanimously 
adopted 6 and so their implementation in clinical practice is still currently scarce 4.  
Therefore, we have considered that evidence was lacking identifying and validating the available 
systems and variables that can be used to predict DFU development. Studies intending to improve 
the evidence level around the identification of the diabetic foot at risk, to promote the use of a 
standardized foot assessment in daily clinical practice and consequently reduce DFU occurrence were 
needed to be conducted.  
 
LOWER EXTREMITY AMPUTATION IMPACT AND PREDICTION 
On the other extreme of the diabetic foot disease spectrum, several studies concluded that subjects 
after a major LEA reported a poorer quality of life when compared to those with other DM-related 
complications, including end-stage renal disease (ESRD) or blindness 16. A recent study observed that 
patients after a major LEA presented a mortality rate comparable to patients with systemic malignant 
disease, with median survival rates of 40–55 months 21. 
It was reported that once a DFU occurs it will take, on average, 3-4 months to heal, in those 
subjects that the DFU heals 25% will present a re-ulceration, but 25% will require a LEA 7. In the 
population with DM, LEAs are 15 to 40 times more frequent than in persons without DM 1,22. DFU 
is the major predisposing factor for non-traumatic LEA, preceding about 85% of them 6,22. 
Furthermore, after a LEA the risk of an additional one is of 50% in 5 years and the mortality rate is 
of about 70% 17,22.  
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A stratification system for DFU prognostic assessment, highlighting the most predictive factors 
for LEA, is an essential decision-making tool in daily clinical practice, facilitating clinical decisions 
and communication among different health professionals, standardizing the prognostic estimation 
itself 23-26 and the DFU treatment efficacy and allowing specialized centres audit and comparison 26,27.  
However, it is not unusual to find patients with DFU without their feet ever examined (including 
in hospital care) 19,28. Some patients, even with a LEA performed in the same institution, are still 
found not to attend to the respective clinic 29. Likewise, DFU treatment is frequently focused 
exclusively on the wound itself and not taking in consideration the underlying contributing factors 30.  
A study reported that the definitive care referral was delayed in more than one third of patients 
with infection or gangrene and that it was due to an underestimation of severity and poor ischemia's 
detection 31. As a result, it often occurs that the access to specialized care of patients in need is being 
denied due to clinics’ overbook with less urgent patients 4.  
Again, we considered that evidence was lacking around the identification and validation of 
classification systems and independent variables used for LEA prediction. There is also still an 
insufficient use of classifications to improve DFU development and LEA occurrence risk assessment 
in daily clinical care. So, we supposed that the creation of an easy and intuitive classification, with 
two distinct parts; the first part consisting on a classification proved valid for DFU occurrence 
prediction and the second on DFU characterization variables, which could be used for the prediction 
of both outcomes; would be pertinent to improve clinicians’ adherence.  
For all this, this Thesis will address DFU prediction and prognosis classification systems for 
stratifying subjects by their risk of DFU and LEA, respectively, and intends to improve knowledge 
and quality of care on diabetic foot. 
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The final goal of this project was to improve knowledge and quality of evidence on the DFU 
development and LEA occurrence prediction. As final goal we intend to propose an easy to collect 
and apply prognostic stratification system valid both for DFU development prediction (in patients 
without DFU) as well as for DFU poor prognosis (namely LEA occurrence), by adding a few DFU 
characterization variables. To achieve this ultimate objective several steps were necessary.  
In order to describe in detail this process, our research was divided into 3 main sections:  
 
1. For the DFU Prediction we aimed to  
a. retrieve, through systematic reviews, all the stratification systems created 
and variables assessed for the DFU development prediction with DM but 
without active DFU, and 
b. validate and compare all the available systems for DFU development 
prediction in a consecutive series of patients without active DFU.  
 
2. For the DFU Prognosis our main goals were to  
a. retrieve, through systematic reviews, all the stratification systems created 
and variables assessed for the LEA prediction in subjects with DM and 
active DFU, and 
b. validate and compare all the available systems for DFU worst prognosis 
prediction (meaning LEA) in a consecutive series of patients with active 
DFU. 
 
3. At the end of these sections we intend to 
a. propose a unified system proved valid for DFU development prediction 
(retrieved from section 1) that, with the inclusion of additional DFU 
characterization variables (retrieved from section 2), can also accurately 
predict LEA in patients with active DFU. 
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CHAPTER 3: BACKGROUND 
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3.1 CLINICAL DECISION RULES 
 
DEFINITION  
 
 
Health professionals and policy makers have the need to make predictions on several aspects of 
health care and services 1. However, in clinical practice, we observe variability among patients’ 
characteristics; clinical conditions’ causes, presentation, and natural history; and also impact of 
treatment. So, a single variable is seldom sufficient to adequately estimate the patients’ probability to 
have or to develop a given clinical condition, and health professionals tend to use multiple predictors 
to do it 2.  
A multivariable approach for the prognostic studies’ design and analysis is needed to identify the 
most important group(s) of predictive variables and give outcome probabilities for each group, as 
also to create tools to estimate such probabilities and classify subjects by their risk of developing the 
outcome of interest. Such tools are defined as prognostic or prediction models, risk scores, prediction 
or clinical decision rules 2,3.  
Although the methods that will be described in this section were not always applied for the 
creation of the tools that we will study in this Thesis, systems to stratify subjects by their risk of 
outcome development we have considered these systems also as clinical decision rules. 
We have made such decision based on these risk stratification systems’ or classifications’ clinical 
purpose, meaning, to improve prognostic estimation by the use of a group of predictive variables and 
to group subjects with a similar probability to develop such outcome. 
This Thesis focus is on the prediction of diabetic foot outcomes (namely DFU and LEA), so we 
have considered that a chapter concisely explaining how such risk classification tools are developed 
and should be assessed, was considered to be of paramount importance. 
A clinical decision rule (CDR) is created with the purpose of accurately estimating the probability 
of a particular clinical outcome to be present (diagnostic context) or occur in the future (prognostic 
context), and therefore can be applied both in healthy or in ill subjects 1,4. 
A CDR should include the “best” predictor variables, be the smallest possible, easy to use in 
practice and, above all, accurate and generalizable. The predictive probability can be extracted and 
depicted in several ways. 
 Using logistic regression, the formula for the prognostic index (PI) corresponds to the sum score 
by adding our model curve intercept (α) and each combination of the regression coefficients (β) with 
the predictive variables (α+ β*predictive variable); the score chart uses rounded values of the 
regression coefficients (for example by multiplying each one for 10) and presents a final score that is 
calculated by adding each predictive variable related value and a constant; and the nomogram, uses 
the same principle of the score chart but uses a visual graphic aid 1,3,4. 
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STAGES OF DEVELOPMENT AND RESPECTIVE MEASURES 
 
Derivation (or development) 
 
In this stage, the multivariable prognostic model (CDR) is created, by identifying the most 
important predictive variables and assigning relative weights to each one 4,5. 
Before starting this stage one must select the clinically relevant predictive variables for possible 
inclusion in the CDR and the procedure to use with possible missing data. Then, make data handling 
decisions, define the strategy for selecting the most important variables and the procedure to use with 
continuous variables and measures 5. 
The statistical methods more commonly used to develop CDR are logistic and Cox regression 
(when time to event is considered) 4, as they allow probability’ estimation of a particular outcome. 
In order to detect which variables should be included in the multivariate analysis (pre-selection 
screening), some authors consider that they should be identified based on physiological plausibility, 
clinical reasoning, opinion of experts and previous studies’ results 1,4,5; others prefer to include only 
those that were associated with the outcome in the univariate analysis (although this is not considered 
as the most recommended) 1,4. 
Concerning missing values, some statistical techniques (namely multiple imputation) can be used. 
An influence on the assumptions can occur and increase with the number of missing data, as they are 
rarely random. If all subjects with missing values are not considered it can lead to a loss of statistical 
power as well as to incorrect CDR’s and predictive variables’ estimates. When less than 5% of 
observations are missing, a complete case analysis may be considered reasonable 5. 
There are several strategies to select the predictive variables that should be tested to be included 
in the CDR. 
The full model approach consists on including all the considered pertinent predictive variables in 
the CDR. Some authors consider that this method avoids overfitting and selection bias. However, 
the full model is frequently difficult to define as several preliminary choices must be made and it is 
impractical to include all candidates 5. 
The backward approach, the most commonly recommended technique, begins with all the 
candidate variables. A significance level, often 1, 5 or 10%, is considered beforehand. Analysis starts 
with all candidate variables in the model. Hypothesis tests are sequentially applied to identify if a 
given variable should be removed from the model 4,5. The variable with the highest p value is excluded 
in each round and the model is rerun each time. 
The forward method can also be used, however it tends to lose more variables. This method uses 
the opposite logic. Analysis starts with no variables in the model. Hypothesis tests are sequentially 
applied to identify if a given variables should be included in the model 4,5. The variable with the 
highest predictive variable is included in each round and the model is rerun each time. 
The advantage of these selection methods is the fact that they are easy to do, using the same 
variables and selection criteria the results are the same, and they allow to develop smaller models 6. 
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However, we should bear in mind that, by using different methods, the final model is different 
(especially when more candidate predictive variables are tested), regression coefficients can be 
overestimated [especially when the events per variable problem (EPV) occurs, meaning, there are less 
than 10 events per predictive variable tested 2,4] and the distinction between “true” and “false” 
predictive values is hard. 
In each stage of the CDR development one should assess the final model calibration and 
discrimination ability (procedures will be described latter in this section). 
 
Validation 
 
The validation process determines to what extent the CDR is adequate or optimistic, by 
comparing the values of calibration and discrimination of the CDR derivation set to a different one 
4. Preferably, using a prospective cohort design, in each participant the CDR’s predictive variables 
and the outcome are collected and the CDR’s performance is quantified 7. A poor performance of 
the CDR can be due to design or methodologic limitations during the derivation process, the lack of 
inclusion of an important predictive variable in the CDR and/or the existence of substantial 
differences between the derivation and validation settings 4,8. 
 
The internal validation is conducted in the same setting and with similar subjects in which the CDR 
was derived 4. The quality (performance) of the CDR is always better in the derivation dataset than 
in a new one, even when the new samples are derived from the same population 3,4. When the 
derivation sample is small, this optimism is even more pronounced 3,5.  
One of the recommended methods used for internal validation is cross-validation 4. In this technique, 
the available sample is randomly divided in distinct sets: one for the CDR development and the 
remaining to test it. This procedure is conducted repeatedly and the performance estimate 
corresponds to the average value 3,4.  
Another recommended method is bootstrapping 1,4. In this technique we randomly select subjects 
from our dataset, one by one, but each time the subjects stays in the sample set (so he can be selected 
several times) 1,4. This procedure is repeated until we achieve the desired sample size and replicate to 
have several bootstrap samples (usually 250, and at least 100) 4. We simulate that we are making the 
prediction rule in comparable “new” datasets. We then determine the optimism of our CDR on 
calibration and discrimination and calculate the shrinkage factor 1,4. To do so, we apply our prediction 
model to all bootstrap samples. Due to the correlation between our sample and the bootstrap 
samples, the CDR will have higher regression coefficients and AUC. We then apply the CDR on the 
original sample set. The difference observed between each bootstrap sample and our original sample 
set is the average overestimation value, the value we need to correct (the shrinkage factor). We can 
then “adjust” our original CDR 1,4. 
Non-random splitting by clinical centre reduces the sample similarities, which may be considered 
as preferable 8.  
 
Temporal validation is considered as an intermediate between internal and external validation and 
corresponds to a sample splitting by time. There will be several similarities between the two sets. 
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However, this is a prospective evaluation of the CDR, independent from the original dataset and 
derivation process 8. 
In this type of validation, the calibration and discrimination values of the CDR derivation set will 
be compared to another from a more recent time period from the same setting 8.  
 
In the external validation we are quantifying the CDR’s optimism and testing the CDR’s 
generalizability by applying it to a new dataset 3,4,8.  
In this stage, we assess if the performance of the CDR in this new dataset from a different setting, 
through calibration and discrimination measures, is similar to the one reported in the derivation 
process 4,8 or in the previously described validation methods. 
The CDR is optimized for our dataset as regression techniques use, techniques that minimize 
errors for that dataset. There are several factors that can change the CDR calibration in a new dataset 
during the validation process, such as different prevalence of outcome, predictive variables’ 
distribution, data collection, etc. In addition, a regression coefficients overestimation (overfitting) 
could have occurred and a correction (shrinkage) must be conducted, or new variable(s) need to be 
included 8.  
 
Study designs used for derivation and validation 
 
Several study designs can be used for CDR’s derivation and validation, depending on its purpose. 
For a diagnostic CDR, the most commonly used design is a cross-sectional study, in which the 
predictive variables are collected (derivation) or the CDR applied (validation) in a group of patients 
suspected of having the outcome condition 1,4. There is usually a time interval between the collection 
of the predictive variables or the application of the CDR and the reference standard application to 
detect the presence of outcome. The reference standard is the method considered as the accepted 
best available method to determine the presence or absence of the outcome of interest 1,4,9. Ideally, 
the same reference standard should be applied to all participants 1,4,9. 
The time interval should be as short as possible to impede further disease evolution or the 
beginning of treatments 4. Due to the existence of this period, it is unclear if this study methodology 
is a clear cross-sectional or a diagnostic cohort study 4.  
The outcome collection should be blind for the presence or absence of the predictive variables, 
and vice-versa 4,9. 
For a prognostic CDR, the most frequent design is a prospective or retrospective cohort study 
4,10. Subjects with specific characteristics are included in the study, predictive variables are collected 
and then they are followed over a specific period of time and outcome occurrence or absence is 
registered 4. 
A prospective design, with a consecutive inclusion 9, is preferable, due to the possibility of 
controlling the measurement of all the pertinent predictive variables and outcome(s) and the use of 
the most adequate methods to do so 4. 
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Individual participant data from multiple original studies, large data sets from national or 
international surveys or registries, and meta-analytic techniques are becoming more commonly used 
to develop or validate CDR 4. 
Sample size for derivation studies should be calculated considering the need of at least 10 outcome 
EPV and/or the precision required for CDR diagnostic accuracy measures 1,4. For validation studies, 
it is considered that sample size should include a minimum of 100 events and 100 non-events and/or 
the precision required for CDR performance measures 4. 
 
Measures used for derivation and validation 
 
Calibration is defined as the agreement between the predicted probabilities of the studied outcome 
and the observed outcomes in our sample 3,4. This CDR property is usually assessed through the 
calibration in the curve, the Hosmer and Lemeshow test, and the calibration in the large. 
The calibration curve can be used both in the derivation and validation processes and arranges the 
predicted probabilities from low to high by, usually, making groups of deciles of predicted 
probabilities 1,2. The predicted probability in each decile is compared to the observed probability, 
meaning, the observed outcome divided by the total number of subjects in that group.  
This can be depicted in a scatter plot (calibration plot) with the predicted probabilities plotted 
compared to the observed probabilities 3,5,8. The optimal calibration curve shows a 45º line, an 
intercept (α) of 0 and a slope (β) of 1, and a correlation coefficient of 1. The observed and the 
predicted probabilities always agree 1,3,5. When this slope is smaller than 1 it means that optimism 
occurred, the predictions are too extreme, that is, the estimates for low probabilities are too low and 
for high probabilities too high 1,3. On the other hand, if this slope is larger than 1, it indicates that 
probabilities are not extreme enough 1,3.  
When the slope is different than 1 and simultaneously the intercept is different from 0, the 
interpretation is difficult as both are related. This is commonly observed in external validation studies 
and indicates that patient characteristics that were not included in the CDR had a different 
distribution in the development when compared to the validation sample 1,3.  
The Hosmer and Lemeshow test evaluates the same thing as the calibration curve, this is, the goodness 
of fit 1,5,8. However, both should be always used, as they complement each other. This test sums all 
the differences between the predicted and the observed probabilities of each group (for example, 
predicted probabilities percentiles, prediction intervals or covariate patterns) and follows a Χ2 
distribution 1,3,8. The null hypothesis of this test is that there is agreement between these two values, 
therefore with a p value superior to 0.05 we cannot reject it, and so consider that there is goodness 
of fit. However, there is no accepted value range (but the higher the better), the test is sensitive to 
the choice of groups, has poor power to identify miss-calibration in small samples, and is over 
sensitive in large samples (that is, even small disagreements between predicted probabilities and 
observed frequencies originate a statistical significant test value) 1,3,5. 
The calibration in the large is used when validating the CDR in a new patient database and evaluates 
how different is the sum of all the predicted probabilities when compared to the number of observed 
outcomes 1,3. Differences (mis-calibration) can be due to very different observed outcomes or 
problems in our CDR generalizability. Optimism of the CDR, using this measure, is represented by 
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a higher value of the sum of the predicted probabilities when compared to the number of observed 
outcomes 3. 
Another measure is the absolute difference between the predicted and the observed probabilities 3. 
 
Discrimination evaluates how well the CDR distinguishes between people who actually have the 
outcome and those who do not 4. A model with high discrimination usually represents a larger model, 
with a high number of included variables, and therefore gives a lower calibration. On the other hand, 
a model with high calibration is more commonly a smaller model, with few variables included, and 
present lower discrimination 1. A good CDR should have in consideration the best equilibrium 
between these two properties. 
This CDR’s property can be assessed graphically by visualising the validation plot, this is, a boxplot 
with the predicted probabilities distributions per outcome value (absent and present), analysing the 
R2 value or the receiver operating characteristic (ROC) curve, or numerically through concordance-
statistic (c-statistic), the area under the ROC curve (AUC), and accuracy measures (namely, sensitivity, 
specificity, predictive values and likelihood ratios) when applying cut-offs 3,5,8. 
In the case of a discriminative CDR, the validation plot will show a spread of the predicted 
probabilities distribution that is wide and distant from the mean probability 3. This is a very 
informative tool, although there is no quantification of the discrimination 3. 
The R2 evaluates the amount of explained variation of the risk by the CDR and corresponds to 
the square of the correlation between the observed and the predicted probability 1,2,4,5.  
The c-statistic represents the chance of a patient that will have or has the outcome condition to 
have a higher expected probability when compared to a patient that will not or does not have the 
outcome condition 2. This measure is mainly used to assess the presence of optimism. When there is 
a substantial decrease of this value in a new dataset, optimism is considered to be present 3. However, 
this value also depends on the predicted probabilities distribution. For samples with more 
homogeneous predicted probabilities, meaning, without extreme values, the c-statistic value will be 
lower 3. 
For binary outcomes, the c-statistic is equal to the AUC 3,4. ROC curve and respective AUC are 
not very responsive, meaning, the inclusion of a new variable does not make substantial changes and 
so it is hard to test potential improvements 5.  
The ROC curve is a plot of true-positive (sensitivity) versus false positive rate (1-specificity) for 
each value or cut-off points of the predicted probability. The AUC gives the probability that a subject 
with the outcome has a higher predicted probability when compared to one without, for a random 
pair of subjects, consisting of one with and the other without the outcome 1. A value of 0.5 is 
considered as a useless CDR and a value near 1 as perfect discrimination 3.  
Sensitivity is the proportion of subjects with the disease that were adequately identified by the 
CDR as having the disease. Specificity is the proportion of subjects without the disease that were 
adequately identified by the CDR as not having the disease 1,11.  
Positive predictive value (PPV) is the proportion of subjects that were classified as having the 
disease by the CDR (positive) that in fact have the disease. Negative predictive value (NPV) is the 
proportion of subjects that were classified as not having the disease by the CDR (negative) that in 
fact did not have the disease 11. 
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Likelihood ratios show the probability of having a specific CDR result in those that have the 
disease in comparison to those that do not have it 11. Positive likelihood ratio (LR+) is the probability 
of having the disease in those classified as positive by the CDR, in comparison to (meaning, divided 
by) the probability of not having the disease in those classified as positive by the CDR, this is, 
specificity divided by 1-specificity 11. The higher the value, the best the discrimination is. On the other 
hand, negative likelihood ratio (LR-) is the probability of having the disease in those classified as 
negative by the CDR in comparison to (meaning, divided by) the probability of not having the disease 
in those classified as negative by the CDR, this is, 1-specificity divided by specificity 11. The lower the 
value, the best the discrimination is. 
 
Refinement (or Updating) 
 
Developing a new CDR for each time period, context, institution or country may look tempting. 
However it diminishes the results’ generalizability, makes it hard to decide which one to select for 
our context, and overfitting is more probable (due to the need of larger samples for derivation) 4.  
It is preferable, if necessary, to improve calibration by changing only the intercept or both the 
intercept and the slope and/or discrimination by considering the inclusion of a new variable on the 
CDR 4,7.  
The refined CDR’s discrimination can be compared to the original one by several methods: R2, 
comparing AUC, integrated discrimination improvement, and reclassification tables. 
Using the R2 it is possible to compare the amount of explained variation of the risk by the original 
CDR with the new version. However, it is hard to clinically interpret its value 4.  
The AUC value evaluates the CDR’s discrimination 11. We can analyse if the refined CDR has a 
statistically significant higher AUC by comparing its 95% confidence interval (CI) with the one from 
the original CDR 11. However, we cannot understand if the change of the AUC will be clinically 
relevant. 
The integrated discrimination improvement corresponds to the difference between the predicted 
probabilities in those with or that developed the outcome in comparison to those who did not 4.  
The reclassification method evaluates if there is a shift of the subjects to an appropriate risk category 
after adding a new relevant predictor. It is calculated how many subjects in which the outcome 
occurred were reclassified from low to a high risk category (desirable) and from high risk to a low 
risk category. In the same way it is calculated how many subjects in which the outcome did not 
occurred were reclassified from a high to a low risk category (desirable) and from a low to a high risk 
category 4. 
The net reclassification improvement is calculated by subtracting the number of subjects in which 
a desirable reclassification occurred to the number of subjects in which reclassification was occurred 
in a undesirable direction 4.  
After updating the CDR, the new version must be validated in a new setting. 
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Clinical impact 
  
Calibration and discrimination assess the CDR’s performance over the complete range of 
predicted probabilities, but considering that all values are equally relevant 3. It can be appropriate to 
predefine what will be considered as an acceptable calibration and discrimination. And if such values 
are achieved, the CDR may be considered as suitable for clinical practice. Although it is unclear what 
should be considered as satisfactory, prognostic estimations will be required and even moderate 
performances may be translated on an improvement of health professionals’ own assessments 8.   
CDRs are intended to be used in new populations, contexts, countries and time periods. However, 
it is common to observe that CDRs developed in secondary care settings usually have a diminished 
performance when applied in the primary care setting 4,7. This occurs due to a different case-mix, this 
is, a different outcome or predictive variables’ distribution that can lead to a different predictive 
variable – outcome association 4. A validation on different contexts should be performed before 
application in clinical practice 7. So, for an optimized usability of the CDR, there should be a clear 
definition of the predictive variables and outcome, collected through methods that are reproducible 
and available in clinical practice 7. 
Real clinical impact is measured by assessing if the CDR will be helpful to the clinician in decision 
making, whether to request tests or decide treatment strategies 2,3,7, and is independent of calibration 
and discrimination of the CDR.  
In a clinical impact study it is quantified the effect of the CDR on health professionals’ behaviour 
(measured by decision modifications), patient (measured namely by pain, quality of life, satisfaction) 
or clinical outcomes (measured namely by number of events, risk measures), and/or cost-
effectiveness [measured namely by incremental cost effectiveness ratio (ICER)]  in comparison to 
standard care 4,7. For such studies, a control group is required and a randomized controlled trial (RCT) 
is the preferred design 4,7. Randomization can be done by patient, by health professional, or by centre. 
The last is considered as the best method, because it avoids contamination between groups 7.  
Another possible design is a before and after study, with the same health professionals and centres. 
However, temporal changes in clinical methods can affect the results 7. 
An intermediate method between validation and clinical impact assessment are modelling 
techniques or Markov chain models, evaluating the potential gains of using the CDR on clinical 
practice 7. 
 
REPORTING: THE TRIPOD STATEMENT 
 
 
In 2015, a group of specialists developed the TRIPOD guideline: Transparent Reporting of 
multivariate prediction model for Individual Prognosis Or Diagnosis. This checklist addresses the 
reporting requirements for the development and validation of CDR for prognosis and diagnosis in 
all health topics using any kind of predictive variables 4.  
This statement was created based on a systematic search, on several databases, identifying articles 
where recommendations were made for reporting multivariable prediction models and their 
development and validation methodological aspects 4. 
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After reviewing the included articles, a total of 129 possible checklist items were identified and 
compiled in a list of 76 candidate items 4. 
A total of 24 experts, including statisticians, epidemiologists, methodologists, healthcare 
professionals and journal editors, had a 3-day meeting for a consensus on whether retain, merge with 
another, or delete each item. A total of 22 items were considered as essential for CDR’s development 
and validation studies’ reporting 4 (see Figure 1). 
This checklist was not used during the majority of this Thesis studies’ conduction, as this checklist 
was published after their conduction. 
 
Section Topic Der Val Item 
TITLE AND 
ABSTRACT 
Title   
Identify the study as developing and/or validating a multivariable 
prediction model, the target population and the outcome to be 
predicted 
Abstract   
Provide a summary of objectives, study design, setting, participants, 
sample size, predictors, outcome, statistical analysis, results and 
conclusions 
INTRODUCTION 
Background   
Explain the medical context (including whether diagnostic or 
prognostic) and rationale for developing or validating the 
multivariable prediction model, including references to existing 
models 
Objectives   
Specify the objectives, including whether the study describes the 
development or validation of the model, or both 
METHODS 
Source of data 
  
Describe the study design or source of data (e.g. randomized trial, 
cohort or registry data), separately for the development and 
validation data sets, if applicable 
  
Specify the key study dates, including start of accrual, end of accrual 
and, if applicable, end of follow-up 
Participants 
  
Specify key elements of the study setting (e.g. primary care, 
secondary care, general population) including number and location 
of centres 
  Describe eligibility criteria for participants 
  Give details of treatments received, if relevant 
Outcome 
  
Clearly define the outcome that is predicted by the prediction model, 
including how and when assessed 
  
Report any actions to blind assessment of the outcome to be 
predicted 
Predictors 
  
Clearly define all predictors used in developing the multivariable 
prediction model, including how and when they were measured 
  
Report any actions to blind assessment of predictors for the outcome 
and other predictors 
Sample size   Explain how the study size was arrived at 
Missing data   
Describe how missing data were handled (e.g. complete-case 
analysis, single imputation, multiple imputation) with details of any 
imputation method 
Statistical 
analysis 
  Describe how predictors were handled in the analyses 
  
Specify type of model, all model-building procedures (including any 
predictor selection) and method for internal validation 
  For validation, describe how the predictions were calculated 
58 
 
  
Specify all measures used to assess model performance and, if 
relevant, to compare multiple models 
  
Describe any model updating (e.g. recalibration) arising from the 
validation, if done 
Risk groups   Provide details on how risk groups were created, if done 
Development 
versus validation 
  
For validation, identify any differences from the development data 
in setting, eligibility criteria, outcome and predictors 
RESULTS 
Participants 
  
Describe the flow of participants through the study, including the 
number of participants with and without the outcome and, if 
applicable, a summary of the follow-up time. A diagram may be 
helpful 
  
Describe the characteristics of the participants (basic demographics, 
clinical features, available predictors), including the number of 
participants with missing data for predictors and outcome 
  
For validation, show a comparison with the development data of the 
distribution of important variables (demographics, predictors and 
outcome) 
Model 
development 
  
Specify the number of participants and outcome events in each 
analysis 
  
If done, report the unadjusted association between each candidate 
predictor and outcome 
Model 
specification 
  
Present the full prediction model to allow predictions for individuals 
(i.e. all regression coefficients, and model intercept or baseline 
survival at a given time point) 
  Explain how to use the prediction model 
Model 
performance 
  
Report performance measures (with confidence intervals) for the 
prediction model 
Model updating   
If done, report the results from any model updating (i.e. model 
specification, model performance) 
DISCUSSION 
Limitations   
Discuss any limitations of the study (such as non-representative 
sample, few events per predictor, missing data) 
Interpretation 
  
For validation, discuss the results with reference to performance in 
the development data and any other validation data 
  
Give an overall interpretation of the results, considering objectives, 
limitations, results from similar studies, and other relevant evidence 
Implications   
Discuss the potential clinical use of the model and implications for 
future research 
OTHER 
INFORMATION 
Supplementary 
information 
  
Provide information about the availability of supplementary 
resources, such as study protocol, web calculator, and data sets 
Funding   
Give the source of funding and the role of the funders for the present 
study 
 
Der: Derivation, Val: Validation 
 
Table 1. TRIPOD statement checklist (adapted from reference number 4) 
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3.2 DIABETES MELLITUS AND DIABETIC FOOT 
EPIDEMIOLOGY AND COSTS 
 
 
In 2015, DM global prevalence was of 8.8%, affecting 415 million people. More than 320 million 
were on their working age (20-64 years). It is estimated that in 2040 this prevalence will increase to 
10.4%, affecting 642 million individuals, due to its rise in every country worldwide 1. 
Diabetes’ prevalence in Europe, in 2015, is slightly higher when compared to the global one (9.1 
vs 8.8%), representing a population of 60 million people. In 2040, it is expected to rise to a prevalence 
of 10.7% and affect up to 71 million people 1. The European country with the highest DM prevalence 
was Turkey (12.8%), and the countries with higher number of habitants with diabetes are the Russian 
Federation, Germany and Turkey 1. Portugal presented a prevalence of 9.9%, which is higher when 
compared to the global and Europe reported values 1. 
In 2013, Portugal also had a higher mean DM related expenditure [2250 vs 1437 United States 
Dollars (USD)] 2. That year the country had 7982 deaths caused by DM 2. Furthermore, it was 
reported that, in 2012, 4683 years of life were lost due to DM in subjects under 70 years 3.  
DM was responsible for more than 10% of hospitalizations, in 2014, in Portugal 3. Circulatory 
system diseases were the most common cause (22%) and 1863 were directly related to diabetic foot 
3. 
Worldwide, 5.0 million subjects aged between 20 and 79 years died, in 2015, due to reasons 
attributed to DM, which represents a 14.5% global prevalence of all-cause mortality among people 
in this age group. Every 6 seconds a person died due to DM. This magnitude is even higher when 
compared to the combination of deaths due to human immunodeficiency virus/acquired immune 
deficiency syndrome or acquired immunodeficiency syndrome, tuberculosis and malaria (3.6 million 
subjects), which are considered as major public health priorities 1. 
In 2013, 1 in 10 deaths in adults (n=619 000) in the Europe Region was DM related. However 
only 10% were individuals under 50 years, which may indicate the existence of responsive health 
systems along with the age distribution of the population 2.  
That year, it was estimated that more than 25% of the global healthcare budget in the Europe 
region was spent on DM, representing a cost of more than 147 billion USD. Norway was the country 
that spent more money with DM (on average 10.368 USD per person and Tajiskitan the less amount 
(87 USD) 2. 
In 2015, there was a global health expenditure from 673 up to 1197 billion USD related to DM 
care, which represents an investment of 1662 to 2886 USD per person with DM 1. The majority of 
global health expenditures for DM were spent on the United States of America, China and Germany 
1.  
Epidemiologists reported that, in people with diabetes, 20-25% of all hospital admission days are 
diabetic foot related 4. This considerable proportion may be explained by the fact that subjects with 
DM are described to have a 15 to 46 times higher risk of LEA in comparison to those without DM, 
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and the risk of a new LEA varies from 9 to 17% after 1 year and 25 to 68% after 3 to 5 years 4. After 
5 years of an LEA occurrence the survival rate decreases to values around 40 to 70% 4. 
Despite the LEA epidemiology importance, the last global study was published in 2000, including 
subjects undergoing LEA from July 1995 to June 1997 from 10 centres with populations greater than 
200 000 in Japan, Spain, Italy, North America and England. The highest LEA observed rates occurred 
in the Navajo population (43.9 per 100 000 people per year for first LEA in men) and the lowest in 
Madrid (2.8 per 100 000 per year). DM was linked with 25 to 90% of LEA 5. 
In 2014, there were 825 minor LEA and 560 major LEA during hospitalization in Portugal. The 
global and the major LEA number in this year were the lowest since the beginning of the National 
Diabetes Observatory, in 2005 3.  
Due to differences in health organization and variable number of multidisciplinary teams for 
diabetic foot care, we observe a great variability in the rate of minor and major LEA by 100 000 
habitants. The lowest occurred in the North region (6.0 and 4.4, respectively) and the highest in 
Alentejo region (15.1 and 7.8, respectively) 3. 
The impact of diabetic foot on subjects’ quality of life is immense. Limited studies have addressed 
this topic and attempted to derive utility values of health states involving DFU and LEA. 
A recent systematic review 6, including studies from EU5 countries (Spain, Italy, France, England 
and Germany), identified 6 studies reporting quality of life (QoL) data in patients with diabetic foot 
complications.  In this review the authors stated that those subjects with DFU presented a lower 
mean score on all the eight SF-36 domains, especially in what concerns physical capacity. In the same 
way, those subjects with non-healed and recurrent DFU showed lower values when compared to 
those with healed DFU, as well as those that underwent a LEA compared to those that did not. 
Another study, estimating utility values for health states observed amongst diabetic foot patients, 
reported values ranging from 0.31 for patients with feet or leg amputated to 0.84 in those without an 
active or previous DFU 7.  
Moreover, diabetic foot complications represent a major economic burden. Several authors 
reported that there is a disproportionate increase in the cost according to the condition severity. For 
example, it was reported that the annual care cost for subjects with DFU, compared to those without, 
is 5.4 higher in the first year after the DFU occurrence and 2.8 in the second and that the cost of the 
most severe DFU treatment is 8 times higher when compared to the less severe 8. 
Considering the costs associated with diabetic foot care, it was estimated, in one study from the 
United States of America, that for subjects with DM and DPN it would be of around 11 billion USD 
and extrapolated that for those with PAD would be of around 17 billion USD, which is similar to the 
annual costs for breast and colorectal cancer in that country 9.  
Other study demonstrated that diabetic foot complications represent an economic and resource 
utilization burden similar to cancer, depression, lung disease and musculoskeletal diseases’ treatment 
6. Several studies, showed that severe DFU and LEA imply a higher per patient average cost when 
compared to other DM related comorbidities, such as non-fatal myocardial infarction, heart failure, 
ischemic heart disease and eye disease 6. 
DFU treatment cost analysis are more frequently conducted by industrialized countries, such as 
United States of America, Sweden and The Netherlands. For these countries, the direct cost estimates 
(in 2010-adjusted USD) have been reported to vary from 3096 USD for a DFU categorized as Wagner 
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1 to 107 900 USD when a LEA is required. In addition, the reported cost only considered direct costs 
and rarely the cost to the patient 10. Data addressing diabetic foot prevalence and costs in Europe will 
be further presented in section 3.4 of this Thesis: diabetic foot care in Europe. So far no study was 
conducted in Portugal assessing the diabetic foot prevention and treatment related costs. 
Despite all these facts, authors believe that the diabetic foot clinical outcome can be greatly 
improved by prompt referral for specialized assessment and treatment 11. In 2012, only 69.4% of the 
population with diagnosed DM had a register of diabetic foot screening in the Portuguese National 
Health System 3. 
Several authors consider that an organized multidisciplinary approach for the high risk patients, 
including extensive patient education, early assessment and aggressive therapies such as 
revascularization procedures and advanced wound-healing techniques, is markedly economically and 
clinically beneficial by reducing LEA and length of hospital stay 4,8. 
A Dutch study reported that the mean total lifetime cost of treating a patient with intensive 
glycaemic control and/or optimal foot care ranged from 4 088 to 4 386 USD. The incremental cost 
per quality adjusted life year gained for patients under both interventions was under 25 000 USD for 
a preventive foot care leading to a decrease in LEA rate superior to 10% 12.  
Using data from the year 2000, a study from Austria reported that an intensified (specialized 
diabetic foot clinic) versus a standard DFU treatment (general practitioners’ clinics) reduced the direct 
costs in 28.9% per patient, per year in a grade A DFU (no infection or PAD), classified according to 
the Texas classification, and up to 49.7% in grade D (with infection and PAD) due to LEA rates 13. 
An Irish Hospital created a Diabetic Foot Clinic with a multidisciplinary team and concluded that 
the number of major LEA reduced from 12 in the 2 years before the clinic (2006-2008) to 7 in the 2 
years after the clinic creation (2008-2010). This reduction represented an overall saving of 111 063€ 
per year after, even after costing diabetic foot clinic related activity 14. 
The Pan American Health Organization studied which were the health service interventions in 
diabetic foot care that were cost-saving and concluded that the most effective were the education of 
patients with DM on recognizing and treating minor foot injuries (expected reduction of 72% of 
LEA), the use of appropriate footwear (expected reduction of 53% of LEA), and improve the access 
to knowledgeable health care personnel (expected reduction of 47% of LEA) 4. 
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3.3 DIABETIC FOOT PATHOPHYSIOLOGY  
 
Diabetic foot screening, through foot examination and identification of those at higher risk of 
developing complications, is commonly underdone both in inpatient and outpatient settings, due to 
asymptomatic nature of DM, a lack of knowledge of routine practice procedures and of time in usually 
busy clinics 1,2. The best way to overcome these barriers is by explaining the diabetic foot 
pathophysiology in a comprehensive but simple way and by emphasizing the importance to DFU 
prevention. 
Many authors consider that DFU pathophysiology is very similar in the majority of the patients. 
They usually arise from the presence of two or more risk factors: DPN, PAD and/or trauma 1,3-8. DPN 
diminishes the patient’s sensitivity and leads to biomechanical and sweat control alterations, which 
causes minor trauma, less skin resistance and an unawareness of the callus and DFU occurrence 1,9. 
PAD can cause skin frailty which, in the presence of trauma (minor or major), increases the risk of 
DFU and impairs healing 9. 
Trauma, DPN and PAD per se can be responsible for DFU occurrence, maintenance, and 
aggravation and increased infection susceptibility, which leads to more severe DFU (See Figure 1). 
 
Figure 1. Main factors responsible for DFU development and maintenance 
 
DIABETIC PERIPHERAL NEUROPATHY (DPN) 
 
Peripheral neuropathy is highly prevalent in individuals with DM, and leads to signs and symptoms 
of motor, autonomic and sensory neuropathy components 1,5-7,9,10. It is estimated that 70 to 80% of 
individuals with DM present alterations in their motor nerve conduction velocity or in their 
electromyography results, even in early stages of DM 5. Many mechanisms have been proposed to 
explain this susceptibility, namely nitric oxid blocking and the Maillard reaction 1. 
Diabetes Peripheral 
Neuropathy
Peripheral 
Arterial 
Disease
Trauma
Infection 
vulnerability
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The first mechanism corresponds to a cellular damage and consequent endothelial dysfunction due 
to maintained hyperglycaemia that inhibits nitric oxide production (a potent vasodilator) and disrupts 
the endothelium-regulated vascular function, also causing platelet aggregation, altered intimal growth, 
and inflammation and atherothrombosis processes. This microangiopathy, affecting the peripheral 
nerves supply, leads to DPN 1. 
The second mechanism, the Maillard reaction, consists on an interaction between reducing sugars 
and amino groups of biomolecules that produce advanced glycation end-products, which, along with 
lipoproteins, have an important role in the pathogenesis of atherosclerosis 1,5. 
Other discussed mechanism corresponds to an alternative metabolic route for the activated glycose 
in the presence of hyperglycaemia and insulin deficit that leads to sorbitol accumulation in the nervous 
system cells and polyols formation, which is linked to a neurologic dysfunction secondary to 
demyelination, axonal degeneration, Schwann cells’ hyperplasia and hypertrophy and ganglionic 
deterioration in the autonomic system 5. 
However, several other DM/ metabolic syndrome-related factors seem to be linked with DPN in 
addition to hyperglycaemia, such as insulin resistance, blood pressure and lipid profile, as well as 
autoimmune and genetic factors 5. 
DPN has a great impact on the subjects’ foot shape, biomechanics and sensation. 
Motor neuropathy causes foot deformity and limited joint mobility, by affecting both intrinsic foot 
and leg muscles, which create points with abnormal foot pressure and hyperkeratotic areas 1,5,6,9,10. 
Autonomic neuropathy corresponds to a damage of the sympathetic nervous system, causing 
arteriovenous shunting, leading to vasodilation of the foot small arteries 6, precapillary sphincter 
malfunction 7, endothelial dysfunction 10 and also alterations in the foot sweat regulation which can 
cause anhidrosis with dry skin and fissures 1,5-7,10. 
Sensory neuropathy diminishes or even eliminates the deep sensation, namely the ability to feel  the 
feet and toes’ positions, as well as the superficial sensation, this is, the ability to feel pain (and so to 
perceive injury), pressure, temperature and proprioception 5,9. The combination of high pressure points 
with undetected repetitive injuries causes local tissue damage, inflammation, tissue death and, at the 
end, DFU occurrence 1,5,8-10. 
In addition, DPN may affect neuropeptides’ production that are crucial to an adequate wound 
healing, as they stimulate cell chemotaxis, growth factor production and cells proliferation, as well as 
modulation of immune defence mechanisms, namely leukocyte infiltration 1. 
It is important to emphasize that, despite the potential loss of protective sensation, neuropathic 
pain is characterized by one or more of the following symptoms that greatly decrease the patients’ 
quality of life: burning, stabbing, shooting, stinging, hyperesthesia and allodynia 1. 
 
PERIPHERAL ARTERIAL AND VASCULAR DISEASE 
 
Ischemic feet present a very fragile skin, which means that a little amount of friction and trauma 
can lead to skin breakdown 1. On the other hand, the lack of oxygen and nutrients can lead to cutaneous 
necrosis 5. Once there is a solution of continuity, infection may settle and, along with a poor blood 
supply, a severe DFU can occur. In that way, it was reported that ischemia is present in up to 90% of 
the individuals with DM that require a major LEA 1. 
PAD is linked to dyslipidemia, insulin resistance, hyperglycaemia, arterial hypertension, collagen 
glycosylation and coagulation mechanism modifications leading to the atherogenic process. This 
atherosclerosis most frequently settles in the femoral, popliteal and tibial arteries 5. 
Although PAD is a macrovascular diabetes-related complication, microvascular dysfunction is also 
commonly and concomitantly present. This condition also decreases perfusion in the foot of 
individuals with DM by inducing arteriovenous shunting, precapillary sphincter failure, microvascular 
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sclerosis, capillary leakage, venous pooling, low oxygen transcutaneous pressure, alterations in 
hormonal activity as well as the inflammatory process in the vessels 1,5,7,10. 
 There are 3 main factors that can explain these alterations: endothelial and smooth muscle cell 
dysfunction and nerve-axon reflex 6. 
It is also frequent to find both PAD and DPN in the same subject. For that reason it is usual to 
examine subjects with DM and severe PAD that do not present severe rest pain or claudication. Thus, 
several authors have discussed the role of genetic factors in the diabetic foot complications occurrence 
3 and the presence of reduced expression of endothelial nitric oxide synthase both in DPN and PAD 
6. 
 
TRAUMA 
 
In most cases an internal or an external trauma is the major precipitant factor for the DFU 
development. DPN or PAD usually do not directly lead to DFU. 
As described before, motor neuropathy causes biomechanical modifications in the foot that, 
together with sweat alterations, lead to the high pressure points and the formation of hyperkeratosis, 
which increases local pressure even more, which is sustained due to loss of the protective sensation 
1,5,6,8,10. This is described as internal trauma and usually occurs in the toes and plantar surface of the 
foot 6. Hyperkeratotic areas, when not removed and without pressure relief techniques, injure the 
surrounding tissues, create a blister and/or haemorrhage that can evolve to a DFU 1,5,6,8,10. 
The most frequent causes of external trauma are ill-fitting shoes that result in a low but continuous 
increase in the foot pressure, and direct trauma (mechanical, chemical or thermic) 1,5. 
 
INFECTION VULNERABILITY  
 
In subjects with diabetes there is a susceptibility to infection, due to altered leukocyte and immune 
functions (characterized by defects on leukocyte chemotaxis, low phagocytosis and bactericidal 
capacity, impaired cell migration, elevated matrix metalloproteinases, etc.), and decrease in host 
resistance, leading to a loss of the human innate barrier. It is therefore common to find fungal infections 
in the skin and nails of individuals with diabetes. This is also associated to a higher risk of bacterial 
infections 1. 
As above explained, a handful of clinical factors are the main responsible for DFU development, 
even if very complex and intertwined mechanisms are also the reason behind DFU chronicity and 
consequent LEA. Throughout this Thesis it will be emphasized the identification of common pathways 
for both outcomes (See Figure 2). Individual predictive factors will be discussed in detail in chapters 
4.1 and 5.1. 
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Figure 2. Diabetic foot ulcer development and maintenance and lower extremity amputation main pathways 
In full lines the pathways to diabetic foot ulcer development (DFU) and in dashed lines to DFU chronicity and lower extremity amputation (LEA).  As one can 
observe, individual or a combination of several pathways can be involved in DFU development, chronicity and consequent LEA.
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3.4 DIABETIC FOOT RECOMMENDATIONS AND 
QUALITY OF CARE 
 
RECOMMENDATIONS 
 
An effort has been made by many societies throughout the years to improve the diabetic foot care 
quality by publishing guidelines on that topic, namely the American Diabetes Association (ADA) 1-3, 
American College of Foot and Ankle Surgeons 4, American Orthopaedic Foot and Ankle Society 
(AOFAS) 5, Infectious Diseases Society of America (IDSA) 6, International Working Group on 
Diabetic Foot (IWGDF), National Institute for Health and Care Excellence (NICE) 7, SIGN 8 and 
Wound Healing Society (WHS) 9. 
The IWGDF has a special role in the creation of the most important guidelines in this area, 
through the International Consensus on the Diabetic Foot 10. This group was created in 1996, in 
Malvern, and in 2000 became a Consultative Section of the International Diabetes Federation (IDF) 
10.  
Due to the level of dissemination of these guidelines around the world, the quality of the methods 
used and the present partnership with the major DM and global health institutes [ADA, European 
Association for the Study of Diabetes (EASD) and World Health Organization (WHO)], we have 
decided to focus and describe the recommendations published by this group. 
The first guidelines published by this group, in 1999, addressed recommendations for the 
management and prevention of the diabetic foot 10 and were translated into 26 languages, with a 
distribution of more than 100,000 copies worldwide 11. 
In this document it was stressed that an adequate foot complications’ prevention should be 
grounded on 5 key elements 10: 
 
1. Identification of the at-risk foot 
An annual evaluation should be performed to identify signs or symptoms of foot 
deformity, DPN, PAD, previous DFU or LEA, and subjects should be assigned to 
one of four risk categories (0 – no DPN, 1 - DPN, 2 – DPN with PAD and/or foot 
deformity, 3 – DPN and history of DFU or LEA). 
2. Regular inspection and examination of the at-risk foot 
Foot examination should be conducted annually in those patients categorized as 
grade 0, every 6 months for those as grade 1, 3 to 6 months for those as grade 2 and 
every 1-3 months for those as grade 3. Such examination should include clinical 
background characterization, foot and footwear examination. 
3. Education of patient, family and healthcare providers 
Patients and their caregivers should be educated about foot care in a structured and 
repeated way in order to increase their foot care knowledge, awareness, self-care 
behaviours and motivation. Tools must be provided to allow them to identify 
potential foot problems and act accordingly. 
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4. Routine wearing of appropriate footwear 
People with diabetes should be encouraged to use adequate footwear in what 
concerns type and size. Patients with DPN should have access to appropriate 
footwear without economic limitations. 
5. Treatment of pre-ulcerative signs 
When any pre-ulcerative sign is observed, it should be treated until full resolution. 
This includes: removing abundant callus; protecting blisters, or draining them if 
necessary; treating ingrown or thickened nails; and, prescribing antifungal treatment 
for fungal infections. 
Diabetic foot care management should provide resources and staffing to educate the people with 
DM and respective caregivers, perform annual foot examination, apply measures to prevent DFU 
development, provide adequate DFU treatment, conduct regular audits and be divided into 3 level 
institutions 10: 
Level 1: General practitioner, podiatrist, and diabetic nurse; 
Level 2: Diabetologist, surgeon (general, orthopaedic, or foot), vascular surgeon, endovascular 
interventionist, podiatrist and diabetic nurse, in collaboration with a shoe-maker, orthotist 
or prosthetist; and 
Level 3: A level 2 foot centre that is specialized in diabetic foot care, with multiple experts 
from several disciplines working together, each specialised in this area, and that acts as a 
tertiary reference centre. 
In Portugal, the National Health System published, since 2001, 3 normative documents with 
recommendations for adequate diabetic foot care. These documents are based on the previously 
described IWGDF recommendations and emphasise the same 5 key elements and 3 levels of diabetic 
foot care management 12-14. In 2010, for the first time, quality evaluation and surveillance indicators 
for diabetic foot care were presented 13. At this moment, a new and more complete normative is 
being conducted for the DFU prevention and treatment. The Candidate is a member of this 
normative Scientific Committee. 
The IWGDF recommendations have started to be based on expert opinion (representatives of 
more than 100 countries around the world and from the majority of disciplines involved in diabetic 
foot care), due to a lack of scientific evidence. From 2007 on they are based on systematic reviews of 
the literature 11. 
Since the first document, they have been updated 4 times (2003, 2007, 2011, 2015). The most 
recent IWGDF recommendations have been launched in May 2015, and were developed in 
association with ADA, EASD and WHO 11. The document has been officially endorsed by the IDF 
11.  The organization decided to change the name from guidelines to guidance and recommendations 
documents. They were based in systematic reviews of the literature and used the Grading of 
Recommendations Assessment Development and Evaluation (GRADE) system. This system allows 
the formulation of recommendation having in consideration both the available evidence quality level 
(based on risk of bias, effect size and expert opinion), as well as its strength (based on the quality of 
evidence, balance between benefits and harms, patient values and preferences and costs) 15. 
More than 80 000 articles were reviewed by 5 working groups composed by 149 specialists and 
corresponding members 16. The guidance documents focused on 5 topics: 
1. Prevention of foot ulcers in at-risk patients with diabetes, 
2. Footwear and offloading to prevent and heal foot ulcers in diabetes, 
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3. Diagnosis, prognosis and management of peripheral artery disease in patients with 
foot ulcers in diabetes, 
4. Diagnosis and management of foot infections in persons with diabetes, and 
5. Interventions to enhance healing of chronic ulcers of the foot in diabetes. 
This section will give emphasis to the first topic as it is more directly linked with this Thesis theme 
and the Candidate was a member of the respective working group. 
The guidance document on the prevention of foot ulcers 17,18 focused only on at-risk patients with 
diabetes, this is, those without an active DFU but with DPN, with or without foot deformity or PAD, 
or previous DFU or LEA. Three groups of interventions were defined and a systematic review was 
conducted separately:  
1. Care: included improvements in care, namely podiatry, chiropody, multidisciplinary 
and integrated care, screening techniques and interventions to promote health care 
professionals knowledge, 
2. Self-management: comprised interventions used to increase patients’ self-
management, namely patient education, foot home monitoring and lifestyle 
interventions, and 
3. Medical: addressed interventions conducted in hospital context (for example surgery 
and therapeutic footwear). 
For the first group of interventions, 3061 articles were identified, for the second were 2641, and 
the third were 2973. An additional 556 trials were retrieved using a trial registries search. In the end, 
74 studies were included for qualitative analysis, but only 30 were controlled (19 randomized and 11 
non-randomized) 18. The risk of bias was scored as very low (n=3), low (n=11) or high (n=17), 
according to the SIGN guidelines 18.  
At the end of this process 13 recommendations were presented separately for outcomes of first 
DFU, first/recurrent DFU, and recurrent DFU 17. 
Although foot screening to identify a person with diabetes at risk of DFU is considered as 
paramount, no study was found assessing its impact on DFU prevention, as well as identifying the 
recommended periodicity, or the best signs or symptoms to screen for. 
Experts strongly recommended that an annual feet examination should be conducted in all people 
with DM to look for signs or symptoms of DPN and PAD (Recommendation 1). In those with DPN, 
experts strongly recommended to screen also for history of previous DFU or LEA, PAD, foot 
deformity, pre-ulcerative signs, poor foot hygiene and inadequate footwear (Recommendation 2). 
In the presence of pre-ulcerative signs it was strongly advised to treat them, including callus, 
blisters, ingrown or thickened nails, haemorrhage and fungal infections (Recommendation 3). However, 
its effectiveness has been never directly evaluated. 
It was highly recommended that to protect their feet, the at-risk patient with DM should not walk 
barefoot, in socks, or in thin-soled standard slippers at home or outside (Recommendation 4), although, 
no evidence was found on this topic. 
Again, no evidence was retrieved, but experts considered that instruction for patients to daily 
inspect their feet and inside their shoes, wash their feet, avoid chemical agents or plasters to remove 
callus, use emollients to lubricate dry skin and cut toe nails straight across could likely help prevent 
DFU (Recommendation 5). 
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Regarding footwear, it was strongly recommended, based on few RCT with high risk of bias, that 
subjects should wear properly fitting footwear and, when a foot deformity or a pre-ulcerative sign is 
present, therapeutic shoes, custom-made insoles or toe orthosis prescription should be considered 
(Recommendation 6). 
Conversely, with a moderate level of evidence, experts strongly recommended that therapeutic 
footwear, with demonstrated effective plantar pressure relief, should be prescribed and patients 
encouraged to wear them in order to prevent recurrent plantar DFU (Recommendation 7). 
Although it was proved that those patients who follow the advice given in education programmes 
are at lower risk of developing a first DFU, no evidence was found on the actual impact on DFU risk 
of foot self-care education. Thus, experts advised, with weak strength, that education should be 
provided aiming to improve foot care knowledge and behaviour, and patient adherence encouraged 
(Recommendation 8). 
For the DFU recurrence prevention, the value of integrated foot care, consisting minimally on 
professional foot care, patient education and footwear provision was assessed in a few articles. 
Experts strongly recommended that it should be delivered to patients at risk and repeated or re-
evaluated once every one to three months (Recommendation 9). 
The other topic, in addition to footwear, that was classified has having a moderate level of 
evidence, was the impact of home monitoring foot skin temperature in DFU development and 
recurrence prevention. However, it was a weak recommendation as this technique may represent a 
daily burden to the patients and false-positive outcomes may unnecessarily stress patients. In addition, 
for now, cost-effectiveness was not evaluated. The idea behind this is for patients to monitor foot 
skin temperatures at home to identify early signs of inflammation and resolve with the care provider 
its cause (Recommendation 10). 
Digital flexor tenotomy should be considered to prevent a toe DFU in case of conservative 
treatment failure in patients with foot deformity and pre-DFU sign or an active DFU (Recommendation 
11). This is a weak recommendation based on low quality evidence, namely retrospective case series. 
Based on few RCTs, but with the same strength and level of evidence that the previous 
recommendation, experts recommended that Achilles tendon lengthening, joint arthroplasty, 
metatarsal head resection or osteotomy should be considered when conservative treatment has failed 
in patients with an active DFU (Recommendation 12). 
Due to a lack of adequately conducted studies and the existence of several non-surgical 
interventions, the use of nerve decompression to prevent DFU was not recommended 
(Recommendation 13). 
While conducting the systematic review and building the guidance document, experts found some 
key controversies. For example, although DPN is considered one of the most important risk factors 
for DFU development, research on its prevention or treatment is very limited.  
The screening topic, on whom, how, when and with which periodicity subjects should be re-
evaluated, has a great lack of solid data. The authors consider that it is crucial to better define the 
patients that will benefit most from preventive interventions. 
There is also a great lack of cost and cost-effectiveness studies for all the interventions included 
in the guidance document. 
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More controlled trials adequately describing the integrated foot care approach provided are 
necessary as well as studies assessing the development, evaluation and implementation of methods 
to improve patients’ adherence to diabetic foot care.  
 
QUALITY OF CARE: THE EURODIALE CONSORTIUM 
 
The Eurodiale consortium was created in 1999 and included health professionals from 14 centres 
located in 10 European countries: Belgium, Czech Republic, Denmark, Germany, Italy, Slovenia, 
Spain, Sweden, Netherlands and United Kingdom 19. 
They aimed to conduct a multicentre prospective observational study to 1) characterize the 
patients and respective DFU, 2) describe the current clinical outcomes and 3) identify the respective 
predictive factors, 4) understand the differences in management strategies among centres, 5) current 
resource use and associated costs, as well as 6) factors related to low health-related quality of life in 
subjects with DFU. Such analysis resulted in the publication of one dissertation 20 and 12 articles 19,21-
31. 
The group has designed the study in a way to allow data collection during daily clinical practice 
and recruited a cohort as much unselected as possible to allow the best characterization of the 
“normal” European patient with a DFU 23. That we know of, there are no more studies auditing the 
diabetic foot care quality in Europe. 
 
Patients’ inclusion and data collection 
 
They have consecutively included subjects with an active DFU presenting for the first time within 
a 12 months period in any of the above mentioned diabetic foot centres from September 1st 2003 to 
October 1st 2004, both inpatients as outpatients. Participants were excluded if their life expectancy 
was inferior to 12 months, were not willing or able to return to the clinic at least once a month or to 
give informed consent 19.  
Follow-up visits were conducted every 4 weeks until healing, major LEA or for a maximum of 1 
year 19. 
A total of 80 items were collected at baseline, using a standardized entry case-report form (CRF), 
by the multidisciplinary members that were previously trained and audited, describing individual and 
disease-specific factors that could influence management strategies and outcome 19. Health related 
quality of life (HR-QoL) was assessed at the first and last visits by the application of the EuroQoL 
quality of life questionnaire (EQ-5d) 19. 
 
Sample characterization 
 
 A total of 1232 subjects were included in the study, with a mean number of included patients by 
centre of 88 (range 40-125). The majority of the cases were referred by general practitioners or were 
self-referrals (63%) 19. 
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At the moment of entry in the study, subjects’ mean age was 65 years, 64% were men, 70% had 
DM for more than 10 years, 32% presented a comorbidity and 27% were hospitalized 19. So, the 
characteristic participants were elderly male with global poor health status and dependent of others 
for their daily activities. Almost one third of the subjects presented a disabling comorbidity such as 
severe visual impairment, heart failure or angina, ESRD or poor mobility 21. 
A total of 144 subjects were lost to follow up due to non-compliance (n=24), impossibility to 
follow the patient (n=25) or care transferred to other specialists (n=29) or other indeterminate 
reasons (n=66) 26. At baseline, these subjects were marginally older with more frequent history of 
heart failure and deeper DFU of longer duration 26.  
PAD was diagnosed in 49% of the individuals, being possibly underestimated due to falsely high 
ankle-brachial index (ABI) values, and DPN in 86%. Additionally, the majority of DFU were infected 
(58%). Infection was more frequent in subjects with PAD 23. 
DFU were more commonly located at the toes (55%), affecting tissue below the subcutis (45%), 
between 1 and 5 cm2 (52%) and between 1 week and 3 months of duration (57%) 23. 
 
Healing prediction: independent variables and risk score 
 
After 1 year of follow-up, 77% of the participants had their DFU healed (with or without minor 
LEA), 12% were still under treatment, 5% had a major LEA and 6% died 26. The majority of the 
subjects had a (neuro-)ischemic DFU (55%) 24.  
It was found that individuals with both PAD and infection had more frequently deep and non-
plantar DFU. Higher age and the presence of comorbidities were also associated with more severe 
DFUs 23. Moreover, patients with PAD presented higher rates of major LEA and mortality 26. 
So, in their next article, the group analysed if the prognostic predictors differed among patients 
with and without PAD. The potential predictive factors were selected through a literature review, 
expert opinion and suitability for clinical practice collection 26. 
The variables associated with low healing probabilities were older age, male sex, larger DFU, heart 
failure, inability to stand or walk without help, ESRD, DPN and PAD. In those patients with PAD, 
DPN was not associated with poorer outcome, and an interaction with infection was observed. In 
fact, those with PAD and infection had a distinctly higher risk of major LEA, when compared to 
those with PAD or infection alone 26. 
The Eurodiale consortium has also derived a risk-scoring rule for the prediction of non-healing 
DFU as, after 1 year of follow-up, 23% of the subjects remained with unhealed DFU 20. Such rule 
was derived and internally validated by using a random bootstrap samples (with replacement) 
technique.  
Such model consisted on a sum of: 
 2 points for each decade of life,  
 5 points if the subject was of the male gender,  
 7 points for a DFU between 1 and 5cm2 or 12 points if larger than 5cm2,  
 4 points for history of heart failure, 
 6 points for inability to stand or walk without help, 
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 8 points for ESRD, 
 3 points for DPN and 
 5 points for PAD. 
This score presented an area under the receiver operating characteristic curve (AUC) of 0.72 [95% 
CI 0.69-0.75) and, a cut-off of 30 points presented a sensitivity of 63%, specificity of 72%, positive 
predictive value (PPV) of 40% and negative predictive value (NPV) of 87% 20. 
To understand the impact of DFU location on the chance of healing, an analysis was made 
including the 1000 patients for which information concerning the specific location of the ulcer was 
available 22. The authors observed that subjects with digital DFU were older and that these ulcers 
were smaller and of shorter duration. DFUs located at the heel were the largest, and occurred in a 
higher number of patients that were unable to stand or walk without help. Plantar DFUs were smaller 
than non-plantar, less frequently infected, and present in patients that less frequently suffered from 
diabetes-related comorbidities 22. 
In fact, DFU location had an important impact on outcome. Heel ulcers took more time to heal, 
in median, and had a lower number of healed DFUs, when compared to those located at the toe or 
midfoot. This difference was maintained even in the multivariate Cox regression analysis. In addition, 
subjects with heel DFUs also presented higher mortality 22. 
In the same way, non-plantar DFU also took longer and were less likely to heal, when compared 
to plantar, but such difference was not observed in the multivariate analysis 22. 
 
Differences in management strategies 
 
When comparing the clinical outcomes among the different centres it was observed that the rate 
of observed healing (including those that underwent minor LEA) varied between 66 and 86%, non-
healing from 4 to 19%, major LEA from 0 to 13% and death from 3 to 19%, after 1 year of follow-
up. The authors reported that these variation could not be explained just by participants’ 
characteristics differences. For example, it was observed that the centres with better outcomes used 
significantly more revascularization and surgical procedures 20. 
As the group has defined healing including those subjects that underwent minor LEA (meaning, 
those occurring below and excluding the ankle level) they have decided to assess differences in minor 
LEA rate and their determinants in the included European countries 30. 
After the 1 year follow up, minor LEA was conducted in 18% (n=194) of the participants: 55% 
toe, 34% ray and 11% midfoot amputations. The risk factors associated with its occurrence, in the 
univariate analysis, were: male gender, increased depth and size, longer existing, and infected DFU, 
foot oedema and PAD. Using logistic regression for multivariate analysis, the identified independently 
associated variables were: male gender, DFU depth, infection and PAD 30. 
This score was transformed into a rule by calculating a disease severity score, for each patient, 
based on the size of the logistic regression coefficients. It is calculated as follows: 
 18 points if deep ulcer 
 6 points if PAD 
 5 points if infected DFU 
 2 points if male. 
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The AUC of this rule was of 0.77 (95% CI 0.75-0.79) for the prediction of minor LEA. 
Rates of minor LEA occurrence varied from 2.4 up to 34%, showing a marked difference. 
However, the mean subjects’ disease severity score also varied greatly. A strong correlation was found 
between these 2 scores 30. 
For all this, one of the articles 24 aimed to determine the patient-related factors and barriers 
influencing diabetic foot management strategies. Multivariable models were created to identify which 
participants’ characteristics predicted the use of total contact casting (TCC) or alternative casting 
techniques in those with plantar fore- or mid-foot DFU and the use of vascular imaging techniques 
in those with severe limb ischemia, non-healing DFU after 1 year of follow-up or undergoing major 
LEA. 
Also, for all episodes that subjects with a neuropathic plantar forefoot DFU were not treated with 
casting techniques and those with severe limb ischemia that did not underwent 
angiography/revascularization, the respective CRFs were checked and reasons for not following the 
current consensus documents were obtained 24. 
The group observed that more than one quarter of the subjects (27%) had been treated for more 
than 3 months in another institution before being referred to the participating diabetic foot clinic, 
varying from 6 to 55% between centres. Most commonly these subjects were being treated in primary 
care institutions (44%); in 35% of the cases a general practitioner and in 12% a chiropodist/podiatrist 
was involved in the DFU care 24. 
Although 41% of the subjects were already treated with offloading at baseline, only in 56% the 
treating physician considered it to be adequately relieving the pressure at the DFU site. So, inadequate 
or inexistent offloading was observed in 77% of the included subjects, independently of the DFU 
duration 24. 
During follow-up, 35% of the participants were treated with some kind of offloading technique, 
varying from 0 to 68% between countries and centres 24. 
Male gender, DFU size and employed status was independently associated with TCC application 
in subjects with forefoot or midfoot DFU 24. 
The reported reasons for underusing casting were: reimbursement policies, lack of qualified staff, 
acceptance by healthcare professionals and by patients 24. 
In what concerns vascular investigation, at baseline, it had been conducted in 53% of the subjects 
with (neuro-) ischemic DFU with a duration superior to 3 months. This percentage was significantly 
lower in those subjects previously treated in primary care centres 24. 
During follow-up 98% of the subjects with PAD underwent functional vascular assessment, 
through transcutaneous oxygen pressure, ankle and/or toe pressure, and 41% vascular imaging, by 
duplex, conventional angiography and/or magnetic resonance angiography. The last percentage 
varied from 14 to 86% between countries and centres 24. 
Vascular imaging was conducted only in 40% of the individuals with chronic DFU that did not 
heal after 1 year of follow-up or that undergone major LEA. The predictors for vascular imaging in 
these subjects and in those with severe limb ischemia were presence of infection and rest pain 24. 
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Reported reasons for the underuse of vascular procedures were the presence of a non-functional 
leg, spontaneous DFU healing, very poor health status of the patient and professional beliefs 24.  
 
Resource utilization and costs associated with DFU treatment 
 
In 2008, the group reported on resource utilization and costs associated with DFU treatment. For 
such analysis they have stratified patients by their disease severity according to the Texas University 
classification (TUC) 25, and only included countries with, at least, 80 participants to guarantee data 
representativeness and reliability. 
Unit costs, from the entry date up to the date of the final visit, for all kind of DFU care resources 
were retrieved, using a specific unit cost form, from 7 out of the 10 participating countries. These 
forms questioned about cost with diagnostic and interventional procedures, off-loading, antibiotic 
therapy, hospitalisation, management by clinical specialists, topical treatment and indirect costs 
(related to loss of production) 25. 
According to the TUC classification, the costs associated with treating a DFU ranged from 4.514€ 
for the group A (no infection or PAD) up to 16.835€ for the group D (with both infection and PAD) 
25.  
The most common diagnostic test used was microbiology, while for offloading techniques were 
temporary footwear and orthopaedic shoes. Costs associated with hospitalization were the highest 
use of financial resources in all outcome groups. The highest total costs were observed in the subjects 
who had undergone major LEA (25.222€) and lower in those with healed DFU (7.722€) 25, 
highlighting the importance of prevention. 
 
Health-related quality of life in subjects with DFU 
 
Regarding the HR-QoL, no information was obtained in 84 subjects and some EQ-5D domains 
were missing in another 60 subjects. These patients presented no differences when compared to the 
1088 that completed the questionnaire 28.  
Overall, participants reported a low HR-QoL, with frequent report of mobility limitation (68%), 
moderate or severe pain/discomfort (85%), some degree of anxiety/depression (41%) but only 29% 
referred self-care problems 28. 
Inability to walk or stand without help was identified as the most important driver of HR-QoL, 
followed by DFU size, C-reactive protein (CRP) and severe PAD. Clinical factors associated with 
poor outcome (namely, infection, PAD and DPN) had a major impact only in the pain/discomfort 
domain 28.  
 
DFU recurrence prediction 
 
After this 1 year follow-up multicentre cohort study, one of the participants’ medical centres 
decided to assess the risk factors for recurrence of DFU after healing during a 3 year follow-up period 
including the patients from the original Eurodiale study that had a healed DFU 31.   
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From the original 120 patients, 93 had their DFU healed but only 73 remained alive and accepted 
to participate in the study. Only 59 patients were regularly monitored for their foot status in the study 
foot clinic. Additionally, 14 subjects were followed at other local foot or surgical clinics. The same 
form, used in the Eurodiale study, was applied to collect data 31. 
 During follow-up, the majority of the patients’ DFU recurred (58%). The recurrence was more 
common after the first year of follow-up (40%). There was no difference in DFU recurrence between 
the subjects monitored in the study foot clinic compared to those followed in the other clinics 31. 
The identified independent predictors of DFU recurrence, through multivariate stepwise logistic 
regression, were plantar location, osteomyelitis, HbA1c superior to 7.5% and CRP superior to 5 mg/l. 
This model identified with 90.5% sensitivity and 55% specificity the predicted probability of DFU 
recurrence 31. 
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INTRODUCTION 
 
Diabetic foot is a multifactorial condition. Understanding how each one of the clinical factors 
involved affects the morbidity risk allows a more comprehensive and rational vision of this problem, 
thus, increasing the efficacy of diabetic foot complications’ prevention and treatment 1. 
In the last guidance document from the International Working Group on Diabetic Foot 
(IWGDF) it was observed that there is a scarcity of robust data concerning how, whom, and when 
diabetic foot screening should be conducted 2. 
A total of five classifications used to stratify subjects by their risk of developing a diabetic foot 
ulcer (DFU) were identified in a systematic review (SR) 3. These classifications were developed or 
validated in high or low risk settings, and no multicentre study was ever conducted. All these 
classifications were validated and compared in a retrospective cohort study conducted in a Hospital 
Diabetic Foot Clinic 4. In this study, no significant statistical differences were observed between 
classifications. Moreover, even in the highest risk groups all positive predictive values (PPV) were 
under 30% and moderate likelihood ratios (LR) were achieved. 
Other SR 5 observed that the association of more than 100 predictive variables with DFU was 
tested in 71 studies. However, each variable’s association with DFU development was assessed only 
by two or fewer studies in about 80% of the cases. This underlined the striking need for more research 
about measurements readily accessible to clinical investigators that may prove valuable in predicting 
foot outcomes. 
For all this, our study main goals were to validate the available DFU development risk 
classifications, assess the predictive value of the included variables, and compare the classifications’ 
accuracy between hospital and primary care settings.  
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As secondary objectives, we intended to assess the improvement in foot self-care habits, their 
impact on DFU risk and to identify which subjects that will adhere to adequate foot self-care habits. 
 
METHODS  
 
Type of study and selection of participants 
A multicentre prospective cohort study was conducted. Subjects with diabetes and without active 
DFU, that underwent diabetic foot screening in different settings; namely the Centro Hospitalar de 
Vila Nova de Gaia EPE (a tertiary Hospital) Diabetic Foot Clinic, from December 2010 to December 
2012; the Unidade de Saúde Familiar Aquae Flaviae, from July 2013 to September 2014; and Unidade 
de Saúde Familiar Santo André de Canidelo, from March to September 2014 (the last are both primary 
care institutions); were consecutively included.  
Those subjects unable to walk and/or to respond adequately to foot examination tests were 
excluded. 
Analysing the results from a retrospective cohort study comparing all the available risk 
classifications 4, we observed that the diagnostic accuracy measures ranged from 9.9% (a PPV value) 
up to 100% [for sensitivity, specificity and negative predictive values (NPV) in several cases]. 
So, for sample size calculation we considered that if we wished to detect a two-sided difference 
of 15% on the 45% specificity value 4 (the scenario that would require a larger sample size) between 
the two settings, for a 95% confidence interval (CI) and a power of 80%, a sample of 186 participants, 
for each setting, was proposed. Allowing a potential loss to follow up of approximately 20% we 
considered pertinent to include 223 subjects per setting, this is, a total of 446 participants.  
This study was approved by the Comissão Nacional de Protecção de Dados (Data Protection 
National Committee) and the Ethical Committees from the Administração Regional de Saúde do 
Norte (North Regional Health Administration) and from each institution where it was performed. 
No adverse event occurred due to the study conduction. 
 
Data collection 
The risk classifications to be validated in this study, selected through a SR 3, were the American 
Diabetes Association (ADA), International Working Group on the Diabetic Foot (IWGDF), and 
Scottish Intercollegiate Grouping Network (SIGN) classifications, the Seattle risk score (both in its 
original and refined version) and the University of Texas Foot Risk System (UTFRS). 
 However, since this SR publication, and that we are aware of, another system to predict DFU 
development was developed that was called PODUS (Prediction Of Diabetic Foot Ulcerations). This 
classification was created using an individual participant data meta-analysis and was also applied in 
our study 6. This classification considered subjects to be at high risk when there was history of DFU 
and as medium risk those with absent sensation to the Semmes-Weinstein monofilament (SWM) 
and/or with an absent pedal pulse in one or both feet. 
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At baseline, we collected demographic and clinical characterization variables, all the variables 
included in the classifications and others considered as pertinent in another SR 5 that was conducted 
to identify DFU occurrence predictive factors.   
Data was recorded using a case-report form previously created and discussed with all the health 
professionals that participated in the variables’ collection. In addition, a manual was developed and 
several formation sessions were performed to standardize data collection, to improve its consistency. 
Variables were collected and registered by several professionals, namely general practitioners and 
nurses in the primary health care institutions and a podiatrist in the Hospital setting, with a variable 
number of years of experience on diabetic foot (from less than 1 up to 7 years). 
Demographic and clinical characterization variables, history of previous DFU, visual and physical 
impairment (according to the SIGN definition 1 were obtained through clinical interview. A recent 
glycated haemoglobin (HbA1c) value, within 3 months, was collected through clinical file consult. 
The presence of foot deformity, hyperkeratosis, tinea pedis, onychomycosis, and history of 
previous LEA and foot self-care habits were collected through foot examination. Previous lower 
extremity amputation (LEA) level was considered as the one with higher level.  
Diabetic peripheral neuropathy (DPN) was diagnosed through a SWM and a tuning fork using 
the procedure described in the IWGDF recommendations 7. Peripheral arterial disease (PAD) was 
considered present in the absence of at least one of the two foot pulses in one or both feet 8.  
Footwear was categorised as low, medium or high risk using the classification proposed by Abbott 
et al 8. In this classification, subjects using more often trainers, lace-ups, boots (low heel), extra 
depth/surgical shoes are categorized as at low risk of developing DFU; subjects wearing “slip-
ons”/casual shoes, bar or buckle fastened shoes or slippers as at medium risk and those using open-
toe sandals, high-heeled shoes or flip-flops as at high risk. 
Measures were registered per individual, this is, when a variable occurred in one or both feet it 
was considered as present. 
DFU was defined as a full-thickness skin defect distal to the malleoli 7.  
Participants were followed for one year or until outcome occurred (DFU) or death. Subjects were 
re-assessed in variable intervals (from 1 to 6 months), according to the IWGDF recommendations 7 
and health professionals’ clinical judgement, and a reinforcement of adequate foot self-care habits 
was made. Participants were also instructed to return to the clinic if any foot complication appeared 
before the next scheduled appointment. 
A participant was considered as lost to follow up when he or she missed the scheduled 
appointment(s) and did not return before the 1 year follow up. When this occurred, the subjects’ 
clinical electronic file and the National Health Platform was consulted to identify if a DFU or death 
occurred in another institution. 
 
Statistical analysis 
Differences between settings and univariate association between variables and DFU occurrence 
assessment of improvement and prediction of adherence to adequate foot self-care habits were 
identified using statistical tests for two independent samples, such as the student’s t test or the Mann-
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Whitney test for continuous variables and Χ2 or Fisher’s exact test for categorical variables. Statistical 
significance was considered when the p value was inferior to 0.05. 
For each DFU risk classification, prognostic accuracy measures were calculated, namely 
sensitivity, specificity, likelihood ratios, predictive values and area under the receiver operating curve 
(AUC) and respective 95% CI. Statistical differences between classifications were assessed by 
comparing prognostic accuracy measures values and respective 95% CI. Statistical significance was 
considered when there was no overlap between the compared 95% CI. 
 
RESULTS 
 
In a median follow up of 12 months (1 to 12), a total of 32 subjects (7%) developed a DFU, 3 
(0.7%) required a minor LEA, 4 (0.9%) a major LEA, 18 (4%) died and 61 (14%) were lost to follow-
up. The majority of the events occurred in subjects followed in the hospital setting, this is, 91% of 
the DFU (n=29), 100% of the minor LEA (n=3), 75% of the major LEA (n=3), 89% of death (n=16) 
and 77% of the lost to follow-up (n=47). 
 
Sample characterization 
A total of 446 subjects were included, 223 from each setting (hospital and primary care). 
Participants had a mean age of 65 years, body mass index of 29 and a diabetes (DM) duration of 13 
years. The majority were male (52%), lived with a companion (91%), had type 2 DM (99%) and used 
only oral anti-diabetic drugs for glycaemic control (69%) (See Table 1). 
No missing data occurred.  
In the primary care setting, subjects were significantly more commonly female, lived alone, had 
lower mean DM duration and HbA1c values, used less frequently insulin and presented less 
frequently any of the DM-related complications. All of the variables included in the available 
classifications were significantly less prevalent in the primary care, except for tinea pedis (See Table 
1). 
 
Variables associated with DFU occurrence  
Analysing Table 1, we can observe that except for tinea pedis and low risk footwear all the 
variables included in the available classification systems were associated with a higher risk of DFU 
development at 1 year, in our univariate analysis. Higher DM duration, insulin use, and the presence 
of more than 1 DPN symptom and pain in rest also presented a statistically significant association 
with outcome. 
 
Classifications validity for DFU prediction  
Using the complete sample, meaning subjects from both the hospital and primary care setting, we 
observed that no statistically significant differences occurred between classifications on sensitivity, 
PPV, NPV and negative likelihood ratio when assembling the medium and high risk groups and the 
low, medium and high risk groups (See Table 2). NPV and negative likelihood ratios were not 
different between classifications when using only the high risk group as cut-off. 
In the high risk group, the Seattle (both the original and the refined version) and the UTFRS 
classifications had lower sensitivity but higher specificity. The SIGN classification presented lower 
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specificity, PPV and positive LR. In this risk group PPV were less than 40% for almost all 
classifications. 
Assembling the medium and high risk groups, the IWGDF, PODUS and SIGN classifications 
presented lower specificity and positive LR. In these risk groups PPV were inferior to 26% in all 
classifications. 
Uniting the low, medium and high risk groups, the Seattle classification in its original version 
showed the higher specificity and positive LR, while the refined version presented the lower 
specificity. 
The observed likelihood ratios are expected to have a moderate impact on the DFU risk 
development likelihood. In the high risk group positive LR were usually between 5 and 10 and the 
low risk group negative LR typically ranged from 0.1 to 0.2. 
Observing Table 3, no differences in the AUC of the classifications were found and all presented 
values equal or superior to 0.75. 
Comparing the classifications’ accuracy between hospital and primary care setting (See Table 2), 
we observe that, for all cut-offs, sensitivity and positive LR are lower in the primary care setting, 
while specificity and negative LR are higher. NPV are similar, and superior to 90%, in both contexts 
using any of the cut-offs and classifications.  
In what concerns AUC (See Table 3), no differences between classifications were found 
considering the complete sample, hospital or primary care setting. In the primary care setting, AUC 
values tended to be lower (without statistical significance). 
 
Foot self-care habits 
At baseline, participants had less frequently an adequate foot skin moisturizing but wore more 
frequently a low risk footwear in the hospital setting, when compared to the primary care setting (See 
Table 1). 
The presence of adequate foot self-care habits at baseline did not have an impact on the 
prevention of DFU development at 1 year (See Table 1). In fact, those in which a DFU developed 
were more prone to adhere to each of the 3 studied parameters. 
So, we studied the impact of the presence of these habits, at baseline, on DFU recurrence. When 
including only subjects with history of previous DFU in our analysis, baseline adherence to each one 
or ≥2 foot self-care habits did not achieved a statistical significant association with the risk of 
outcome development (results not shown). However, those in which a DFU developed were less 
prone to adhere to each of the 3 studied parameters. 
After 1 year of follow-up a statistically significant improvement in adherence to adequate skin 
moisturizing, nail care and footwear was observed, when evaluating the total sample or the hospital 
setting. In the primary care setting, there was not a significant improvement only in adherence to 
adequate nail care (See Table 4).  
Assessing Table 5, we found that those with previous DFU history tended to adhere more 
frequently to an adequate skin moisturizing after 1 year of follow-up; those with lower age presented 
more frequently adequate nail care; and that male gender, higher DM duration, insulin use, presence 
of retinopathy, hyperkeratosis and history of previous DFU and LEA were associated with the use 
of low risk footwear. 
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DISCUSSION 
 
The selection and application of an adequate classification to stratify subjects by their risk of DFU 
development is crucial for a good clinical practice. 
This is the first study prospectively validating all the available classifications in a multicentre 
context, comparing the classifications’ accuracy among them and between the primary care and the 
hospital setting. 
In agreement with our previous study 4, this article concluded that the available classifications are 
equally and highly valid. Therefore one should select which one to apply according to practicability 
and characteristics of each setting. 
Sensitivity and specificity values varied between classifications and cut-off used. 
In all the classifications and for any cut-off, NPV were always superior to 90%. So, one subject 
classified as low risk has a low chance of developing a DFU and should be followed in the primary 
care setting. However, PPV were typically under 40%, which may represent a burden for the high 
risk setting, due to the high number of subjects that will be followed in that context but will not 
develop a DFU. 
Assessing the classifications’ LR, we can observe that to be classified as at high or low risk will 
have a moderate impact on the subjects’ likelihood of developing a DFU, by increasing or reducing 
it, respectively. 
AUC values for the complete sample were generally superior to 0.80, which highlights the high 
validity of the classifications. The lowest values corresponded to the SIGN and UTFRS 
classifications. However, without presenting a statistical significant difference. 
There were differences in subjects’ characteristics and the classifications’ accuracy when 
comparing the primary care to the hospital setting.  
Subjects lived alone more frequently in the primary care setting, which was expected as more lived 
in a rural setting.  
This study was conducted in an Hospital and a primary care institution (USF Santo André de 
Canidelo) located in a city in the North Coast of Portugal, but also in a primary institution in a rural 
region in the interior of the North of Portugal (USF Aquae Flaviae). Our country is considered to be 
one the most affected countries in the European Union by the population desertification. This 
process is defined by the migration flux from rural areas at the interior to urban areas at the coast 
line and affects one third of the national territory. This phenomena leads to family disaggregation, as 
those that migrate are usually the active population, and to interior regions with more poverty and 
aged population. So, aged people from rural areas that have lost his/her spouse tend to live more 
commonly alone due to the fact that their descendants have moved to another region. 
Also, subjects in this context had better glycaemic control and less DM-related complication, 
which was also anticipated. Subjects with more severe complications are usually followed in hospital 
context. 
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Classifications tended to have lower accuracy measures in the primary care setting. We believe 
this occurred for many reasons that we will enunciate next in detail. PPV values are affected by the 
outcome prevalence and in the primary setting DFU occurred in 3 subjects, representing 1% of these 
subjects. 
Independently of the classification used, 75% of the subjects followed in the primary care centres 
that developed a DFU were categorized as being at medium or low risk. This could be due to the 
existence of less experienced professionals that could have missed to diagnose DPN and/or PAD in 
such subjects. Despite the sessions that were conducted in order to improve the standardization and 
quality of such procedures, these variables seem to be experience dependent. 
All the variables included in the classifications, were significantly associated with a higher risk of 
DFU, except for tinea pedis. DPN symptoms, pain in rest and diabetes duration were also a predictor 
of DFU development. These results are in accordance to the previous SR 3 and retrospective cohort 
study 4. On the other hand, DPN and PAD are already included in the available classifications, so, 
no great improvement in their accuracy is expected. Diabetes duration association should be tested 
in multivariate analysis to overcome a potential confounding effect. 
Although nephropathy is considered to be an important variable for DFU risk prediction 9,10, in 
this study no association was found. Nevertheless, in our study it was collected as reported 
nephropathy and the presence of end-stage renal disease was not collected separately.  
Adherence to foot self-care habits at baseline had no significant impact on DFU development 
risk at 1 year. We consider that in order to detect an effect of these habits on DFU prevention a 
longer follow-up would be needed. 
Adequate moisturizing of the skin was more frequent on subjects that developed a DFU. This 
association was linked to the fact that those at higher risk tended to adhere more to foot self-care 
habits. Furthermore this association was not observed when including only subjects with previous 
DFU on the analysis.  
After 1 year of follow-up and education of the participants, an improvement in adherence to all 
of the studied foot self-care habits was observed. The awareness of the magnitude of improvement 
of adherence to foot self-care habits with the surveillance and educational reinforcement during the 
periodical appointments is important to understand the baseline value to which specific educational 
interventions should be compared to. 
It is important to understand which individuals will adhere more easily to the prescribed habits to 
better personalize their education. 
We observed, as anticipated, that older people had less frequently an adequate nail care. The use 
of low risk footwear was more prevalent in male subjects, with higher DM duration, using insulin, 
with retinopathy, hyperkeratosis and previous foot complications. Female subjects are more resistant 
to change footwear due to aesthetic reasons. We consider that a special reinforcement on this care is 
given to those with longer disease duration, DM-related complications and biomechanical alterations. 
In addition, in the hospital setting some of the subjects classified as at high risk with biomechanical 
alterations can have therapeutic footwear free of charge.   
This study has some limitations. Namely, the number of DFU in the primary care setting was very 
low, which greatly affects the diagnostic accuracy measures precision and diminished the PPV values. 
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Some of the researchers had very low experience on diabetic foot and no reliability assessment 
was conducted for the predictive variables detection, the classifications application or outcome 
recognition. This may had an indeterminate effect on the estimated measures. However, by including 
health professionals with different levels of experience we intended to better portray the reality of 
clinical care in this topic. 
The presence of the predictive variables collection and the classifications’ application was made 
and registered before outcome development. So, researchers were not blind to baseline characteristics 
when assessing DFU occurrence. This can lead to an overestimation of the estimated measures. 
There were differences in each institution’s participants’ inclusion period due to the time needed 
to recruit the institutions, to receive ethical consent and to each institution’s logistics. 
Some decisions were made in order to facilitate results’ analysis. When indeterminate results 
occurred, it was considered as the presence of such variable in the individual. 
In line with a previous study 4, we have simplified the DPN and PAD diagnosis by replacing 
vibration perception threshold test by the tuning fork and using only foot pulses to detect the last. 
This may have underestimated the classifications’ accuracy measures. Nonetheless, it simplifies the 
classifications’ application and therefore their use in clinical practice. 
Our results are applicable for all clinical settings. However, our sample was constituted by subjects 
with a mean of 65 years and mainly with type 2 DM (99%), which may impair our results’ 
generalizability. Then again, this reflects the majority of diabetic foot clinics’ population. 
In the primary care setting the outcome prevalence was of 7% and in the hospital setting of 13%. 
Studies published for the prediction o DFU development with 1 year of follow-up 3 reported 
prevalence values of 5.7 (without setting reported), 7.2 (in a multicentre study) and 20.9% (in a general 
internal medicine practice). So, for both settings we had low prevalence values and could not achieve 
the 100 events that are recommended for prediction models validation 11. 
As main strengths our study presents its prospective and multicentre design, including all type of 
health professionals that work on this topic and with different experience levels. The number of 
participants was based on an appropriate sample size calculation. 
No missing data occurred and a comparison of the diagnostic accuracy measures between 
classifications and settings was possible. 
The STARD 12 and STROBE 13 checklists were used to improve reporting. 
We have used a 1 year follow up in accordance to the guidelines, in which a reclassification of 
diabetic foot risk is proposed 2. 
We have studied the impact of foot self-care habits impact on DFU risk, improvement after 1 
year of follow-up and variables’ associated with such adherence. This is a topic for which evidence is 
considered both crucial and scarce 2.  
In conclusion, all the available classifications used to stratify individuals with DM by their risk of 
DFU development showed high and similar accuracy in this external prospective multicentre 
validation study. The follow up of subjects considered to be at low risk in primary care institutions 
and at medium and high risk in hospital institutions is considered as reasonable. 
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The variables included in the classifications were considered as pertinent. DM duration was 
considered as associated with DFU development, in univariate analysis, and is not currently included 
in any classification. 
Foot self-care habits adherence at baseline had no impact on DFU risk development reduction at 
1 year. Those at higher risk tended to adhered more frequently to such habits.  
A significant improvement on these habits adherence was detected during diabetic foot 
surveillance appointments. Nail care should be reinforced and provided specially to older people. The 
aesthetics of low risk footwear should be considered when prescribing them to females. Education 
on the importance of adequate footwear to subjects with more recent diagnosis of DM, without DM-
related and foot complication should be emphasized. 
Further studies addressing the accuracy of the available classifications in the primary care setting 
and the impact of adherence to foot self-care habits on DFU risk at long term are needed. 
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Table 1. Differences between settings and association of the baseline variables with DFU and 
recurrence of DFU 
Variables 
All 
(n=446) 
Hospital 
setting 
(n=223 ) 
Community 
setting 
(n=223) 
p-value 
DFU 
(n=32) 
No DFU 
(n=414) 
p-value 
Subject characterization 
Age (in years) [mean (SD)] 65 (11) 65 (10) 65 (10) 0.7a 68 (12) 65 (11) 0.1a 
Male gender [n (%)] 233 (52) 128 (57) 105 (47) 0.03b 19 (59) 214 (52) 0.4b 
Body mass index [mean (SD)] 29 (5) 29 (6) 29 (5) 0.9a 28 (5) 29 (5) 0.09a 
Lives alone [n (%)] 39 (9) 12 (5) 27 (12) 0.01b 3 (9) 36 (9) 0.9c 
Diabetes characterization and comorbidities  
Type 2 diabetes [n (%)] 443 (99) 223 (100) 220 (99) 0.08c 32 (100) 411 (99) 0.6c 
Diabetes duration (in years) [mean (SD)] 13 (10) 16 (11) 9 (8) <0.001a 18 (11) 12 (10) 0.01a 
Insulin use [n (%)] 136 (31) 106 (48) 30 (14) <0.001b 18 (56) 118 (29) 0.001b 
Reported hypertension [n (%)] 343 (77) 166 (74) 177 (79) 0.2b 23 (72) 320 (77) 0.5b 
Reported myocardial infarction [n (%)] 30 (7) 26 (12) 4 (2) <0.001b 4 (12) 26 (7) 0.2c 
Reported history of stroke [n (%)] 50 (11) 39 (18) 11 (5) <0.001b 7 (22) 43 (11) 0.05c 
Reported retinopathy [n (%)] 111 (25) 90 (40) 21 (10) <0.001b 8 (25) 103 (25) 1.0b 
Reported nephropathy [n (%)] 58 (13) 45 (20) 12 (6) <0.001b 5 (16) 53 (13) 0.7b 
Variables included in the classifications 
HbA1c (in %) [mean (SD)] 7.3 (1.6) 8.0 (1.6) 6.8 (1.4) <0.001 a 8.4 (1.8) 7.2 (1.6) 0.001a 
Visual impairment [n (%)] 159 (36) 115 (52) 44 (20) <0.001b 17 (53) 142 (24) 0.03b 
Physical impairment [n (%)] 124 (28) 91 (41) 33 (15) <0.001b 17 (53) 107 (26) 0.001b 
Foot deformity [n (%)] 250 (56) 184 (83) 66 (30) <0.001b 30 (94) 220 (53) <0.001b 
Onychomycosis [n (%)] 211 (47) 132 (59) 79 (35) <0.001b 22 (69) 189 (46) 0.01b 
Tinea pedis [n (%)] 34 (8) 10 (4) 24 (11) 0.01b 2 (6) 32 (8) 0.8c 
SWM sensitivity altered [n (%)] 137 (31) 88 (40) 49 (22) <0.001b 19 (59) 118 (29) <0.001b 
TFS altered [n (%)] 135 (30) 79 (35) 56 (25) 0.02b 23 (72) 112 (27) <0.001b 
DPN [n (%)] 194 (44) 108 (48) 86 (39) 0.04b 24 (75) 170 (41) <0.001b 
PAD [n (%)] 86 (19) 62 (28) 24 (11) <0.001b 18 (56) 68 (16) <0.001b 
History of DFU [n (%)] 77 (17) 75 (34) 2 (1) <0.001b 23 (72) 54 (13) 0.001b 
History of LEA [n (%)] 26 (6) 24 (11) 2 (1) <0.001b 12 (38) 14 (3) 0.001c 
Low risk footwear [n (%)] 193 (43) 117 (52) 76 (34) <0.001b 14 (44) 179 (43) 1.0b 
Other foot characterization variables not included in the classifications 
More than 1 symptom of DPN [n (%)] 120 (27) 92 (41) 28 (13) <0.001b 17 (53) 103 (25) 0.005b 
Oedema [n (%)] 100 (22) 73 (33) 27 (12) <0.001b 8 (25) 92 (22) 0.7b 
Hyperkeratosis [n (%)] 142 (32) 40 (18) 102 (46) <0.001b 6 (19) 136 (33) 0.2b 
Pain in rest [n (%)] 39 (9) 15 (7) 24 (11) 0.1b 6 (19) 33 (8) 0.04c 
Claudication [n (%)] 49 (11) 31 (14) 18 (8) 0.05b 4 (13) 45 (11) 0.8c 
Adequate skin moisturizing [n (%)] 249 (56) 126 (56) 123 (55) 0.8b 24 (75) 225 (54) 0.03b 
Adequate nail care [n (%)] 354 (79) 162 (73) 192 (86) 0.002b 26 (81) 328 (79) 0.8b 
 
DFU: Diabetic Foot Ulcer; DPN: Diabetic Peripheral Neuropathy; PAD: Peripheral Arterial Disease; reDFU: DFU 
recurrence; SD: Standard Deviation; SWM: Semmes-Weinstein Monofilament; TFS: Tuning Fork Sensation 
 
a: student’s t test for independent samples; b: Fisher’s exact test; c: X2 test 
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Table 2. Diagnostic accuracy measures (in percentages) of the classification systems for DFU development prediction at 1 year in the total sample, the hospital 
and community setting 
DAM 
ADA IWGDF PODUS Seattle Seattle refined SIGN UTFRS 
RG 
Val
ue 
95% 
CI 
RG 
Val
ue 
95% 
CI 
RG 
Val
ue 
95% 
CI 
RG 
Valu
e 
95% CI RG 
Val
ue 
95% CI RG 
Val
ue 
95% CI RG 
Val
ue 
95% CI 
All  
Sens  3 72 56-87 3A+ 
3B 
72 56-87 High 72 56-87 Highest 43 22-64 Highest 38 17-59 High 91 81-100 3 31 15-47 
Spe 87 84-90 87 84-90 87 84-90 95 93-98 96 94-98 58 53-63 98 97-100 
PPV 30 20-41 30 20-40 30 20-40 36 18-55 38 17-59 14 10-19 59 35-82 
NPV 98 96-99 98 96-99 98 96-99 97 95-98 96 94-98 99 97-100 95 93-97 
LR+ 5.6 4.0-7.8 5.5 4.0-7.6 5.5 4.0-7.7 9.3 4.7-18.5 10.2 4.7-21.8 2.2 1.8-2.5 18.5 7.5-45.3 
LR- 0.3 0.2-0.6 0.3 0.2-0.6 0.3 0.2-0.6 0.6 0.4-0.9 0.6 0.5-0.9 0.2 0.05-0.5 0.7 0.6-0.9 
Sens  3+2 84 72-97 3A+ 
3B+ 
2A+ 
2B 
 
91 81-100 High+ 
Med 
91 81-100 Highest 
+  
Next-to-
Highest 
71 52-91 Highest 
+  
Next-to-
Highest 
71 52-91 High+ 
Med 
94 85-100 3+2 72 56-87 
Spe 77 72-81 62 58-67 60 55-65 88 84-91 88 84-91 50 45-54 74 70-79 
PPV 22 15-29 16 10-21 15 10-20 26 15-37 26 15-37 13 8-17 18 11-24 
NPV 98 97-100 99 98-100 99 97-100 98 97-100 98 97-100 99 98-100 97 95-99 
LR+ 3.6 2.9-4.5 2.4 2.0-2.8 2.3 1.9-2.7 5.8 3.9-8.5 5.8 3.9-8.5 1.9 1.6-2.1 2.8 2.1-3.7 
LR- 0.2 0.09-
0.5 
0.2 0.05-
0.4 
0.2 0.05-
0.5 
0.3 0.2-0.6 0.3 0.2-0.6 0.1 0.03-0.5 0.4 0.2-0.7 
Sens  3+2
+1 
94 85-100 3A+ 
3B+ 
2A+ 
2B+ 
1 
94 85-100  Highest 
+ Next-to-
Highest  
+ Next- 
to- Lowest 
86 71-100 Highest 
+ Next-
to-
Highest  
+ Next- 
to- 
Lowest 
95 86-100  3+2
+1 
75 60-90 
Spe 50 45-55 50 45-54 73 68-77 36 31-41 59 54-64 
PPV 13 8-17 13 8-17 16 9-23 8 5-12 12 8-17 
NPV 99 97-100 99 98-100 99 98-100 99 98-100 97 95-99 
LR+ 1.9 1.7-2.1 1.9 1.6-2.1 3.1 2.5-4.0 1.5 1.3-1.7 1.8 1.4-2.3 
LR- 0.1 0.03-
0.5 
0.1 0.03-
0.5 
0.2 0.07-0.6 0.1 0.02-0.9 0.4 0.2-0.8 
Hospital Setting 
Sens  3 79 65-94 3A+ 
3B 
79 65-94 High 79 65-94 Highest 47 25-70 Highest 42 20-64 High 97 90-100 3 34 17-52 
Spe 74 68-80 73 67-79 73 67-79 90 86-95 93 88-97 45 38-52 96 94-99 
PPV 31 21-42 31 20-41 31 20-41 41 20-61 44 21-67 21 14-28 59 35-82 
NPV 96 93-99 96 93-99 96 93-99 92 88-97 92 87-97 99 97-100 91 87-95 
LR+ 3.0 2.2-4.1 2.9 2.2-4.0 3.0 2.2-4.0 5.0 2.5-10.0 5.7 2.6-12.7 1.8 1.5-2.0 9.6 3.9-23.1 
LR- 0.3 0.1-0.6 0.3 0.1-0.6 0.3 0.1-0.6 0.6 0.4-0.9 0.6 0.4-0.9 0.08 0.01-0.5 0.7 0.5-0.9 
Sens  3+2 93 84-100 3A+ 
3B+ 
2A+ 
2B 
 
97 90-100 High+ 
Med 
97 90-100 Highest 
+  
Next-to-
Highest 
79 61-97 Highest 
+  
Next-to-
Highest 
79 61-97 High+ 
Med 
97 90-100 3+2 76 60-91 
Spe 63 56-70 55 48-62 48 41-55 76 69-84 76 69-83 42 35-49 61 54-68 
PPV 27 19-36 25 17-32 22 15-29 32 19-45 31 17-44 20 13-26 23 14-31 
NPV 98 96-100 99 97-100 99 97-100 96 93-100 96 93-100 99 97-100 94 90-98 
LR+ 2.5 2.0-3.1 2.2 1.8-2.6 1.9 1.6-2.2 3.4 2.3-4.9 3.3 2.2-4.7 1.7 1.4-1.9 2.0 1.5-2.6 
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LR- 0.1 0.03-
0.4 
0.06 
0.009-
0.4 
0.07 0.01-
0.5 
0.3 0.1-0.7 0.3 0.1-0.7 0.08 0.01-0.6 0.4 0.2-0.8 
Sens  3+2
+1 
97 90-100 3A+ 
3B+ 
2A+ 
2B+  
1 
97 90-100  Highest 
+ Next-to-
Highest  
+ Next- 
to- Lowest 
89 76-100 Highest 
+ Next-
to-
Highest  
+ Next- 
to- 
Lowest 
95 85-100  3+2
+1 
76 60-91 
Spe 42 35-49 58 51-65 52 44-61 32 24-40 56 49-63 
PPV 20 13-27 25 17-32 21 12-30 16 9-23 20 13-28 
NPV 99 96-100 99 97-100 97 94-100 98 93-100 94 90-98 
LR+ 1.7 1.5-1.9 2.3 1.9-2.8 1.9 1.5-2.4 1.4 1.2-1.6 1.7 1.3-2.2 
LR- 0.08 0.01-
0.6 
0.06 
0.009-
0.4 
0.2 0.05-0.8 0.2 0.02-
1.11 
0.4 0.2-0.8 
Community setting 
Sens  3 0 NA 3A+ 
3B 
0 NA High 0 NA Highest 0 NA Highest 0 NA High 33 0-87 3 
n=0 
NA 
Spe 99 98-100 99 98-100 99 98-100 99 97-100 99 97-100 70 64-76 
PPV 0 NA 0 NA 0 NA 0 NA 0 NA 1 0-4 
NPV 99 97-100 99 97-100 99 97-100 99 98-100 99 97-100 99 97-100 
LR+ NA NA NA NA NA NA NA NA NA NA 1.1 0.2-5.5 
LR- 1.0 1.0-1.0 1.0 1.0-1.0 1.0 1.0-1.0 1.0 1.0-1.0 1.0 1.0-1.0 1.0 0.4-2.1 
Sens  3+2 0 NA 3A+ 
3B+ 
2A+ 
2B 
 
33 0-87 High+ 
Med 
33 0-87 Highest 
+  
Next-to-
Highest 
0 NA Highest 
+  
Next-to-
Highest 
0 NA High+ 
Med 
67 13-100 3+2 33 0-87 
Spe 89 84-93 78 72-83 70 64-76 95 92-98 95 92-98 56 50-63 70 63-76 
PPV 0 NA 2 0-6 2 0-6 0 NA 0 NA 2 0-5 1 0-3 
NPV 98 97-100 99 97-100 99 97-100 99 98-100 99 98-100 99 98-100 99 96-100 
LR+ NA NA 1.5 0.3-7.6 1.1 0.2-5.7 NA NA NA NA 1.5 0.7-3.4 1.1 0.2-5.5 
LR- 1.1 1.1-1.2 0.9 0.4-1.9 0.9 0.4-2.1 1.1 1.0-1.1 1.0 1.0-1.1 0.6 0.1-2.9 1.0 0.4-2.1 
Sens  3+2
+1 
67 13-100 3A+ 
3B+ 
2A+ 
2B+  
1 
67 13-100  Highest 
+ Next-to-
Highest  
+ Next- 
to- Lowest 
50 0-100 Highest 
+ Next-
to-
Highest  
+ Next- 
to- 
Lowest 
100 NA  3+2
+1 
67 13-100 
Spe 56 50-63 56 50-63 86 81-90 38 31-44 62 55-68 
PPV 2 0-5 2 0-5 3 0-9 2 0-4 2 0-6 
NPV 99 98-100 99 98-100 99 98-100 100 NA 99 98-100 
LR+ 1.5 0.7-3.4 1.5 0.7-3.4 3.5 0.8-14.6 1.6 1.5-1.8 1.7 0.8-4.0 
LR- 0.6 0.1-2.9 0.6 0.1-2.9 0.6 0.1-2.3 NA NA 
0.5 0.1-2.7 
 
ADA: American Diabetes Association; CI: Confidence Interval; DAM: Diagnostic Accuracy Measure; IWGDF: International Working Group on the Diabetic Foot; Med: Medium; NA: Not 
Applicable; PODUS: Prediction Of Diabetic Foot Ulcerations; RG: Risk Group; SIGN: Scottish Intercollegiate Grouping Network; UTFRS: University of Texas Foot Risk System 
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Figure 1. Area Under the Receiver Operating Characteristic Curve of the classification systems for DFU development prediction at 1 year in the total sample 
(figure on the left), the hospital (figure in the middle) and community setting (figure in the right) 
   
 
Yellow line: American Diabetes Association; Orange line: International Working Group on Diabetic Foot; Burgundy line: PODUS (prediction of diabetic foot ulcerations); Purple line: Seattle score; 
Lilac line: Seattle categories; Dark blue line: Seattle score; Light blue line: Seattle refined categories; Green line: Scottish Intercollegiate Guidelines Network; Violet line: University of Texas 
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Table 3. Area Under the Receiver Operating Characteristic Curve of the classification systems for DFU development prediction at 1 year in the total sample, the 
hospital and community setting 
Classification 
All Hospital setting Community setting 
AUC 95% CI  AUC 95% CI  AUC 95% CI  
ADA 0.86 0.76-0.95 0.84 0.76-0.93 0.51 0.14-0.87 
IWGDF 0.86 0.77-0.96 0.86 0.77-0.94 0.48 0.15-0.80 
PODUS 0.86 0.77-0.95 0.83 0.75-0.92 0.60 0.19-1.00 
Seattle (continuous) 0.86 0.78-0.95 0.82 0.72-0.92 0.70 0.39-1.00 
Seattle (categorical) 0.85 0.75-0.94 0.81 0.70-0.92 0.67 0.26-1.00 
Seattle Refined (continuous) 0.88 0.81-0.96 0.83 0.73-0.93 0.92 0.88-0.95 
Seattle Refined (categorical) 0.84 0.74-0.93 0.81 0.70-0.91 0.67 0.43-0.90 
SIGN 0.75 0.66-0.84 0.74 0.64-0.83 0.46 0.16-0.75 
UTFRS 0.77 0.65-0.89 0.77 0.64-0.89 0.52 0.17-0.88 
 
ADA: American Diabetes Association; CI: Confidence Interval; IWGDF: International Working Group on the Diabetic Foot; PODUS: Prediction Of Diabetic Foot Ulcerations; SIGN: Scottish 
Intercollegiate Grouping Network; UTFRS: University of Texas Foot Risk System 
 
 
Table 4. Improvement of foot self-care habits after 1 year of follow up 
 
Adequate skin moisturizing  Adequate nail care Low risk footwear 
Baseline After 1 year  p-value Baseline After 1 year  p-value Baseline After 1 year  p-value 
Total sample [n (%)] 249 (56) 240 (72) <0.001a 354 (79) 298 (89) <0.001a 193 (43) 178 (53) 0.006a 
Hospital setting [n (%)] 126 (56) 95 (72) <0.001a 162 (73) 113 (86) <0.001a 117 (52) 80 (61) 0.04a 
Community setting [n (%)] 123 (55) 145 (72) 0.002a 192 (86) 185 (91) 0.3a 76 (34) 98 (48) 0.006a 
 
a: Fisher’s exact test; b: X2 test 
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Table 5. Variables associated with good foot self-care habits after 1 year of follow up 
Variables 
Adequate skin moisturizing Adequate nail care Low risk footwear  
Yes 
(n=240) 
No 
(n=95) 
p-
value 
Yes 
(n=298) 
No 
(n=37) 
p-
value 
Yes 
(n=178) 
No 
(n=157) 
p-value 
Subject characterization 
Age (in years) [mean (SD)] 65 (10) 66 (10) 0.7a 65 (10) 70 (9) 0.006a 65 (10) 65 (11) 0.6a 
Male gender [n (%)] 120 (50) 48 (50) 0.9b 148 (50) 20 (54) 0.4b 103 (58) 64 (41) 0.004b 
Body mass index [mean (SD)] 30 (6) 29 (5) 0.4a 29 (6) 29 (5) 0.9a 30 (5) 29 (6) 0.9a 
Lives alone [n (%)] 22 (9) 7 (7) 0.8b 26 (9) 3 (8) 1.0b 14 (8) 15 (10) 0.6b 
Diabetes characterization and comorbidities  
Type 2 diabetes [n (%)] 238 (99) 91 (96) 0.2b 296 (99) 33 (89) 0.3b 176 (99) 152 (97) 1.0b 
Diabetes duration (in years) [mean (SD)] 12 (11) 12 (9) 1.0a 11 (10) 14 (10) 0.1a 13 (10) 7 (2) 0.03a 
Insulin use [n (%)] 63 (26) 23 (24) 0.9b 77 (26) 9 (24) 1.0b 55 (31) 30 (19) 0.03b 
Reported hypertension [n (%)] 187 (78) 70 (74) 0.6b 230 (77) 27 (73) 1.0b 135 (76) 121 (77) 0.5b 
Reported myocardial infarction [n (%)] 12 (5) 5 (5) 0.8b 15 (5) 2 (5) 0.7b 12 (7) 5 (3) 0.2b 
Reported history of stroke [n (%)] 24 (10) 9 (9) 1.0b 30 (10) 3 (8) 1.0b 17 (10) 16 (10) 0.9b 
Reported retinopathy [n (%)] 46 (19) 20 (21) 0.6b 59 (20) 7 (19) 0.8b 44 (25) 21 (13) 0.01b 
Reported nephropathy [n (%)] 23 (10) 10 (11) 0.7b 32 (11) 1 (3) 0.2b 20 (11) 12 (8) 0.4b 
Variables included in the classifications 
HbA1c (in %) [mean (SD)] 6.9 (1.4) 7.2 (1.6) 0.2a 7.2 (1.6) 7.0 (1.5) 0.5a 7.2 (1.7) 7.1 (1.4) 0.4a 
Visual impairment [n (%)] 75 (31) 27 (28) 0.7b 88 (30) 14 (38) 0.2b 62 (35) 39 (25) 0.07b 
Physical impairment [n (%)] 53 (22) 23 (24) 0.7b 69 (23) 7 (19) 0.8b 46 (26) 29 (18) 0.1b 
Foot deformity [n (%)] 122 (51) 41 (43) 0.3b 145 (49) 18 (49) 0.7b 96 (54) 67 (43) 0.08b 
Onychomycosis [n (%)] 105 (44) 36 (38) 0.5b 122 (41) 19 (51) 0.1b 83 (47) 58 (37) 0.1b 
Tinea pedis [n (%)] 19 (8) 11 (12) 0.3b 24 (8) 6 (16) 0.1b 16 (9) 14 (9) 1.0b 
SWM sensitivity altered [n (%)] 66 (28) 29 (31) 0.6b 86 (29) 9 (24) 0.8b 58 (33) 36 (23) 0.09b 
TFS altered [n (%)] 68 (28) 20 (21) 0.2b 78 (26) 10 (27) 0.7b 48 (27) 39 (25) 0.8b 
DPN [n (%)] 98 (41) 39 (41) 0.9b 122 (41) 15 (41) 0.7b 78 (44) 58 (37) 0.3b 
PAD [n (%)] 36 (15) 14 (15) 0.2b 43 (14) 7 (19) 0.5b 32 (18) 18 (11) 0.3b 
History of DFU [n (%)] 32 (13) 5 (5) 0.05b 35 (12) 2 (5) 0.4b 30 (17) 7 (4) <0.001b 
History of LEA [n (%)] 11 (5) 1 (1) 0.2b 12 (4) 0 (0) 0.6b 11 (6) 1 (1) 0.007b 
Other foot characterization variables not included in the classifications 
More than 1 symptom of DPN [n (%)] 225 (94) 75 (79) 0.4b 281 (94) 34 (92) 0.3b 170 (96) 144 (92) 0.6b 
Oedema [n (%)] 38 (16) 23 (24) 0.08b 52 (17) 9 (24) 0.2b 37 (21) 24 (15) 0.3b 
Hyperkeratosis [n (%)] 79 (33) 36 (38) 0.5b 104 (35) 11 (30) 0.5b 64 (36) 51 (32) 0.02b 
Pain in rest [n (%)] 20 (8) 10 (10) 0.5b 26 (9) 4 (11) 0.5b 15 (8) 14 (9) 0.8b 
Claudication [n (%)] 23 (10) 9 (9) 1.0b 28 (9) 4 (11) 0.6b 19 (11) 13 (8) 0.6b 
 
DFU: Diabetic Foot Ulcer; DPN: Diabetic Peripheral Neuropathy; PAD: Peripheral Arterial Disease; SD: Standard 
Deviation; SWM: Semmes-Weinstein Monofilament; TFS: Tuning Fork Sensation 
a: student’s t test for independent samples; b: Fisher’s exact test; c: X2 test 
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This Thesis addresses the prediction of diabetic foot complications (DFU and LEA). Although 
an adequate stratification of subjects by their risk of these outcomes to occur is the pillar stone for a 
correct and rational allocation of human and economic resources in clinical practice, until now, no 
classification or stratification system has been widely adopted for none of both outcomes. 
Furthermore, despite its importance, research on diabetic foot and respective funding are still 
scarce. For example, between 2002 and 2011 the National Institutes of Health (NIH) funded a total 
of 22.531 projects in diabetes from which only 33 (0.15%) were on DFU, corresponding to a 
7.161.363.871 United States Dollars (USD) and 11.851.468 USD (0.17%) funding, respectively 1. In 
the same way, between 2010 and 2011 the Diabetes UK received 402 grant applications, from which 
only 15 were diabetic foot related and only one of these was funded 1. 
 
MAIN FINDINGS 
 
With our research, we believe to have achieved our purpose of increasing the available evidence 
on this topic, by identifying the predictive variables and systems created for DFU and LEA prediction 
and externally validating such systems.  
 
Diabetic foot ulcer prediction 
 
In our first systematic review with the aim of identifying the available evidence on DFU risk 
stratifications systems (or classifications) 2, we concluded that 5 systems had been published until that 
time: ADA, IWGDF, SIGN, Seattle System from Boyko et al and University of Texas. The articles 
addressing this topic were scarce (n=13), for some of the systems accuracy measures were not 
possible to retrieve and external validation was never conducted.  
DFU prevalence ranged from 5% (community setting) up to 34% (high risk/ hospital setting) and 
classifications had diverse structures and included a different number and type of variables. It was 
possible to determine accuracy measures in 4 studies only for 3 out of the 5 classifications.  
On the other hand, DPN, PAD, foot deformity and previous DFU and LEA were included in 
the majority of the systems and accuracy measures were similar and robust. 
We must highlight that just 2 of the classifications were developed using multivariate regression 
techniques (UT and Boyko et al). The Boyko et al (or Seattle classification) was the only classification 
that underwent external validation, reported AUC value and assessed the impact of time on the 
classification’s accuracy. 
The IWGDF classification is the most disseminated classification and it is even included in the 
National Health Systems’ recommendations documents on diabetic foot in some countries, such as 
Portugal. However, further external validation is necessary and includes ABI and VPT measurements 
for the identification of PAD and DPN, respectively, which are not easily collected in all clinical 
contexts. 
The Boyko et al system requires a spreadsheet to conduct the necessary calculus and the cut-off 
values are hard to memorize. 
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The SIGN classification, uses only easy to collect variables and has an easy classification system, 
with subjects with no risk factor being classified as low risk, with one risk factor as moderate risk and 
with two or more as high risk. However, this classification includes the higher number of variables 
(n=8). 
For all this, it was not possible to select the “best” classification system to be used in all or in each 
setting. 
While reviewing all the predictive factors associated with DFU 3, we have included 71 studies 
studying more than 100 variables. Again, DFU prevalence varied greatly. For first DFU development 
it ranged from 5.0 to 7.2%; DFU recurrence from 15.5 to 60.5%; and DFU history prevalence from 
10.4%, in a Norwegian community based study, up to 48.0%, in an Indian hospital based study. 
In this study 2, we have observed that risk factors for DFU development, assessed in five or more 
studies, considered as predictive in the majority of studies (3 or more) included higher diabetes 
duration, HbA1c, DPN diagnosed through VPT at malleoli and SWM, higher PPP, PAD, previous 
DFU and LEA; as unrelated in all studies included diabetes type; and as predictive of uncertain value 
included higher age and male gender.  
In general, risk factors considered in four or fewer studies were of uncertain significance with the 
exception of height, DPN diagnosed through tuning fork, NDS, thermal sensitivity or MNCV, first 
MTPJ mobility and daily activity due to predictive ability in all the studies or large cumulative study 
sample size. Education degree was never associated with any of the outcomes.  
We emphasize that all of the available DFU risk stratification systems previously reviewed by our 
group included variables that were demonstrated to significantly predict DFU development (DPN, 
PAD, foot deformity and previous foot complications). For some the evidence was not as compelling, 
as for example physical impairment (included in the SIGN classification) and tinea pedis (included in 
the Boyko et al classification). High HbA1c value (included in the Boyko et al classification) was 
considered to be associated with DFU development in various studies, although not in all.  
Only previous DFU was significantly associated with DFU recurrence in more than one study. 
However, generally studies’ sample sizes were insufficient to detect association between variables.  
We have also concluded that several important predictive variables’ collection procedure; namely 
for SWM perception, PAD diagnoses through pulses palpation, PPP and footwear risk classification; 
in what concerns cut-off definition is widely variable. This is of paramount importance as the SWM 
and pulses palpation are included in almost all the DFU development risk classifications.  
In addition, the association between each predictive variable and DFU development was assessed 
only by two or fewer studies in 76% of the cases and with DFU recurrence or re-ulceration in 90%. 
This underlined the striking necessity for more research on measurements that are readily accessible 
to clinical investigators and may prove valuable in predicting these foot outcomes. 
In what concerns DFU development or recurrence prevention measures the available evidence is 
almost inexistent, with 6 studies published assessing the prevention of DFU development and 5 of 
recurrence; and include education, clinical care and dermal thermometry. Furthermore, only one 
study was conducted assessing the impact of foot self-care habits on DFU development prevention. 
These results highlight the fact that several clinical decisions (selection of team elements, type of care 
provided, advices given and reinforced in each appointment) are not evidence-based. 
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There is some reassurance that the variables used for the identification of the foot at risk are 
adequate, although their collection is still not sufficiently standardized. But, with our first systematic 
review 2, due to a low evidence level, we could not select which system to apply in clinical care. As 
for predictive variables few of them had compelling evidence stating their association with a high risk 
of DFU 3.  
After retrieving all the available evidence around this topic, we considered pertinent to conduct a 
retrospective cohort study validating simultaneously all the existing diabetic foot risk stratification 
classification systems 4. This study helped to understand the classification systems’ performance in a 
high risk setting, to evaluate the independent variables predictive value and to allow future studies’ 
sample size calculation.  
Foot deformity, PAD, DPN and previous diabetic foot complications were again associated with 
higher DFU development risk. All the classifications were highly and equally accurate, especially 
sensitivity, specificity, NPV and AUC. PPV values were under 30% for all classifications. Some 
differences were observed between the accuracy values found in our study when compared to the 
studies included in our systematic review for which such measures were available. 
However, several questions remained, namely if the systems would be equally valid also in the 
primary care context, if using an higher sample size any statistical significant difference would be 
found between systems and if it would be relevant to include new predictive variables. For all this we 
considered pertinent to prospectively validate all the classification systems in a multicentre context, 
to assess differences on participants’ characteristics and classifications’ performance according to the 
institution of origin and to test the relevance of including new predictive variables (submitted for 
publication). 
Both in the retrospective 4 as in the prospective multicentre validation (submitted for publication) of 
the available systems, we concluded that the systems were comparable and valid to classify subjects 
by their risk of DFU at 1 year. High AUC, NPV, sensitivity and specificity values and moderate LR 
were observed. Only PPV values were considered to be modest (under 30-40%). This implies that 60 
to 70% of the subjects categorized at high risk of DFU development will not develop one. This can 
occur due to several reasons, namely the prevention techniques’ effectivity or misclassification, and, 
in both cases, a high level of resources are being spent unnecessarily.  
Differences were found on subjects’ characteristics and systems’ accuracy when comparing the 
hospital with the primary care setting. It is needed to further study the impact of the setting on the 
systems’ accuracy and understand if such variation is just prevalence dependent. 
At 1 year, an improvement on adherence to foot self-care habits was observed in both contexts. 
However, adherence at baseline was not associated with a reduction on DFU development risk. A 
study with longer follow-up should be conducted. 
Our results did not support the need to include any variable to improve diagnostic accuracy of 
any classification and none of the classifications outperformed the remaining.  
In addition, it is described 5-7 that subjects should have their risk of DFU development reclassified 
each year. However, there is no evidence substantiating this periodicity. Studies with longer follow 
up should be conducted in order to identify any significant loss of the systems’ accuracy as well as to 
quantify the annual progression from each risk group to another. 
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Diabetic foot ulcer prognosis 
 
In our systematic review with the aim of identifying the available evidence on LEA risk 
stratification systems (or classifications) 8, we concluded that 15 had been published (8 systems for 
the description and 7 for the prognostic assessment of active DFU), assessed on 25 articles.  
As in the DFU prediction, we observed that outcome prevalence was highly variable (6.4 to 
33.3%) and that the classifications had different structures.  
DFU area, depth, infection, PAD, DPN and foot deformity were the most commonly included 
variables. DFU area, depth, infection, gangrene, PAD and DPN were the most studied predictive 
variables and for which meta-analysis was possible to conduct. DPN and DFU area presented the 
highest sensitivity; gangrene the highest specificity, and positive and negative LR. Pooled AUC values 
were similar and ranged from 0.65 to 0.74. 
Foot deformity, PAD and DPN are included in almost all classifications used both for DFU 
development and LEA prediction. DFU depth, the presence of infection and gangrene are the most 
commonly used variables for DFU characterization in daily practice, even when no specific 
classification is being used. Our data supports the collection of such variables and the selection of a 
classification that includes them. 
The most frequently validated classifications were the Meggit-Wagner, S(AD)SAD and TUC. 
However, all of them have several clinical use limitations. The Meggit-Wagner is considered to be 
too simple and lacking on DFU description details. The S(AD)SAD classification, although it includes 
just easy to collect variables, it has a complex and hard to remember structure. The TUC classification 
is the only one with a bi-dimensional structure and includes depth, ischemia and infection. However, 
area is not included and some authors considered it difficult to use in daily clinical care. 
Accuracy measures were highly variable and not always possible to extract. There is a lack of 
external validation studies for the available systems. Reported LR for all systems were usually below 
5, from 1.3 to 6.9, and are expected to have little to moderate effect on clinical decision.   
We were not able to distinguish any classification performance and select the one that should be 
widely implemented.  
The Eurodiale consortium published a group of studies conducted in 10 European countries 
evaluating the DFU care, namely clinical outcome, patients’ characteristics and quality of life and 
barriers to adequate care delivery 9. To contextualize our classification systems’ validation results, we 
considered imperative to understand the quality of diabetic foot care in Portugal 10. So, we performed 
a cohort study assessing the clinical outcome of all patients scheduled for a specialized diabetic foot 
clinic, the setting in which the majority of the studies were conducted, and compared the results to 
the ones reported by the Eurodiale consortium.  
In comparison to the Eurodiale studies, our sample was slightly older, with deeper and more 
severe DFU and frequently located at the toes. Despite this, we had similar healing, major LEA and 
mortality rates, but inferior rates of minor LEA and hospitalization. So, we consider that the results 
of the next study are generalizable to Europe. 
Due to the need of improving the classifications’ evidence level and to allow, for the first time, a 
direct comparison, we have conducted a prospective cohort study simultaneously validating all the 
identified classification systems and assessed the pertinence of the included predictive variables 11.  
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In this study, we verified that all systems were associated with LEA, had equivalent and good 
accuracy measures values, especially high NPV and specificity.  However, once more, PPV were 
considered to be small (under 30%) and sensitivity and LR were only modest. 
When comparing the results in our cohort to those retrieved in our systematic review, some 
differences were observed. Several systems (SIGN, DEPA and IDSA-IWGDF) underperformed in 
our cohort, particularly in what concerns specificity values. For the DUSS, SWESS, SINBAD, TUC 
and van Acker-Peter systems this was the first time that diagnostic accuracy measures were reported. 
In this study we have confirmed that the majority of the most commonly used variables for the 
DFU development risk assessment (namely, deformity, PAD and previous foot complications) were 
associated with LEA prediction in those subjects with active DFU, in the univariate analysis. PAD 
and previous DFU were associated with LEA occurrence even in the multivariate analysis. 
However, it was not possible to select the “best” system to use in clinical practice and potential 
for enhancement was detected.  
 
DIAFORA  
 
This last study, is the epitome and integrates the results of all the previous ones.  
In the first systematic review and validation studies we have concluded that no DFU development 
risk classification could be selected has the best one for dissemination and clinical adoption. On the 
other hand, the IWGDF has been widely disseminated and is in fact included in the Health ministry 
guidelines for adequate diabetic foot care in several countries, in which Portugal is included (since 
2011).  
As for LEA risk prediction, several classifications exists but adoption in clinical practice is very 
scarce and both our systematic review and validation study could not identify which one should be 
selected. We have also observed that room for improvement existed. Thus, we have considered that 
the creation of a new classification easy to use, to memorize and with properties that could improve 
adherence would be pertinent. 
We have observed in our studies that DPN, PAD, foot deformity and previous foot complications 
were frequently associated and included both in classifications to predict DFU development as well 
as LEA occurrence.  
So, using the same cohort of participants 12 in which the previous study was conducted, we were 
able to create a classification system composed by two sections, named DIAFORA.  
The first section, is intended to be used on subjects without DFU and includes DPN, PAD, foot 
deformity and previous DFU (the same to say the IWGDF classification).  
Once DFU occurred, the addition of DFU characterization variables (such as, multiple DFU, 
infection, gangrene and bone affection) makes the classification system full version adequate to 
predict LEA occurrence.   
We consider that this group of variables, besides statistical significance, is also 
pathophysiologically reasonable. The DFU development most common pathway results from the 
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presence of two or more of these risk factors: DPN, PAD and/or trauma. Trauma can be external, 
direct or indirect (for example caused by ill-fitting shoes), or internal, caused by foot deformity.  
A DFU history implies that several of these factors are present and so the risk of a new occurrence 
is higher. When such DFU requires a LEA, biomechanical changes will also occur and high pressure 
points will exist. 
Such factors are also linked to a poor DFU prognosis. The presence of DPN, by diminishing the 
pain, may delay the patient search for the health professionals and adequate treatment. Furthermore, 
the presence of DPN is associated with changes in neuropeptides production and thus to an 
inadequate healing. PAD diminishes the tissue perfusion and alters the inflammatory process. Several 
factors also link the presence of DPN and PAD to each other. 
The presence of a DFU in a foot deformity site will increase the pressure, and adequate offloading 
techniques are needed to stop the continuous lesion of the tissues and enable healing. 
As for DFU characterization variables, tissue necrosis and gangrene are linked to the presence of 
PAD and infection. The adequate removal of inviable tissue can lead per se to the necessity of a LEA. 
The treatment of infection in the diabetic foot, especially when severe and/or in the presence of 
PAD, can be very difficult and lead to cellulitis, abscess and/or osteomyelitis that can quickly spread 
to the leg and require an emergency LEA. When in the presence of DPN, it is common that patients 
will only detect the presence of their DFU when the infection signs are visible and has already spread 
throughout the tissues. 
When a DFU reaches the bone, it has usually a long duration and represents an open gateway for 
infection and osteomyelitis that destroys greatly the bone structure and consequently alters the toe or 
foot biomechanics. When in the presence of PAD, osteomyelitis’ conservative treatment is very 
challenging and frequently LEA is required to clean the infected bone and surrounding tissues. 
Multiple DFU usually occur in subjects with PAD, DPN and/or global health debilitation. They 
also represent several opportunities for infection to install by the presence of several sites with skin 
breakdown as well as by the possibility of inter-contamination. Furthermore, it impairs the effectivity 
of local offloading techniques in active subjects.  
Besides the reasonability of the included variables, DIAFORA had a comparable or higher 
accuracy measures’ values when compared to the existing ones. The results showed that, using the 
DIAFORA system, those subjects classified as low risk can be safely followed in primary care 
institutions and those as medium or high risk should be urgently sent to specialized care. 
We consider that our DIAFORA classification has some advantages. For example, we believe that 
the fact that it is composed by a classification that is already used for the identification of diabetic 
foot at risk worldwide, and by four additional variables, that are currently empirically used by the 
majority of the clinicians in daily practice, is expected to help memorization and adoption.  
In addition, we have chosen to use only easy to conduct data collection procedures and to 
transform the score in a round point system that can be straightforwardly calculated to facilitate 
application in clinical practice.  
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MAIN LIMITATIONS 
 
This Thesis has some limitations. Studies evaluating the reliability of predictive variables and 
stratification systems for both outcomes were very limited. We have already developed a protocol to 
overcome this lack of evidence and the respective study is under ethical approval to be performed 
on a Hospital setting. However, we could not conduct them during this Thesis execution. 
The fact that almost all the studies were conducted in a high risk setting results’ generalisability 
may be reduced and participants’ characteristics may be more homogeneous which may alter the 
classifications’ accuracy. 
For both outcomes, we have chosen to simplify the DPN and PAD diagnosis (by using the tuning 
fork instead of the VPT, for the first; and by using just foot pulses palpation, for the second) to 
standardize these variables’ collection and to better mimic the instruments available in most clinical 
settings. In the future, it is important to address the real impact of these modifications on the systems’ 
accuracy measures and understand if these procedures implications significantly decrease their 
validity. 
On the other hand, the cut-off for DPN diagnosis using the SWM (number of locations where to 
apply) and for PAD using foot pulses palpation (number of absent pulses) is still not standardized. 
Further studies are needed addressing this topic. 
Additionally, although diabetic foot risk assessment is considered to be important for the 
respective complications’ prevention, we still do not know how effective they really are. A recent 
systematic review 13, assessing the effect of diabetic foot screening, was able to retrieve only 2 RCTs 
and 4 before and after studies addressing this topic. Several authors reported that, there is insufficient 
evidence to support foot screening as an effective intervention in the DM population 13,14.   
 
FUTURE RESEARCH 
 
Research assessing the true impact of diabetic foot screening, based on risk stratification 
conducted by any of the available systems, on reducing DFU and LEA and improving resources 
utilization is indispensable.  
In sum, the following research questions are still to be answered: 
- Are the variables included in the DFU and LEA prediction systems reliable? 
- Which are the best procedures to screen for DPN, PAD and high foot pressure? 
- Which is the best group of variables to predict DFU recurrence? 
- Which is the best group of variables to predict LEA occurrence? 
- Do the available classifications systems for DFU and LEA prediction will have significantly 
different accuracy measures when validated in different settings and countries? 
- Is it possible to improve the systems’ accuracy, especially PPV and LR? 
- Does DIAFORA classification presents equal accuracy in other contexts? 
- Which is the best periodicity to conduct diabetic foot risk assessment? 
- Which is the impact of diabetic foot screening on DFU and LEA reduction? 
- Is diabetic foot screening and prevention techniques cost-effective? 
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